• Abstract and Figures
• Public Full-text

CURRICULUM VITAE

NAME Chinthalapally V. Rao, Ph.D.

Professional Address Department of Medicine Hematology/Oncology Section University of Oklahoma Health Sciences Center OU Cancer Institute 975 NE 10th Street, BRC 1203 Oklahoma City, OK 73104 Phone: (405) 271-3224 FAX: (405) 271-3225 Email: [email protected]

EDUCATION Ph.D. 1983-1987, Microbiology Department of Microbiology Osmania University, Hyderabad, India

M.S. 1981-1983, Microbiology Department of Microbiology Osmania University, Hyderabad, India

B.S. 1978-1981 (Biology, Chemistry and Microbiology) Osmania University, Mahabubnagar, India

PROFESSIONAL EXPERIENCE

9/2004- Present Professor and Kerley-Cade Chair in Cancer Research Department of Medicine, Hem/Onc Section University of Oklahoma Health Sciences Center Oklahoma City, OK

7/2009- Present Director, Center for Chemoprevention and Cancer Drug Development OU Cancer institute, OUHSC, Oklahoma City, OK

6/2006- 7/2009 Chairman, Scientific Advisory Committee OU Cancer Institute, OUHSC, Oklahoma City, OK

9/2004- 7/2009 Director, Chemoprevention Program OU Cancer Institute, University of Oklahoma Health Sciences Center, Oklahoma City, OK 2/2005-Present Professor, Graduate School, OUHSC, Oklahoma City, Ok 12/2004-Present Professor of Pathology (Adjunct), Department of Pathology, OUHSC 10/2001- 6/2004 Chief, Division of Nutritional Carcinogenesis, American Health Foundation Cancer Center (AHFCC) Rao/CV 2

NCI-designated Cancer Center Valhalla, NY 10595

10/2001- 9/2004 Program Leader, Nutritional Carcinogenesis and Chemoprevention Program, AHFCC, Valhalla, NY

10/2001-8/2004 Member, NCI-Clinical Nutritional Unit, AHF, Valhalla, NY.

4/1996- 9/2001 Co- Program Leader, Nutritional Carcinogenesis and Chemoprevention Program, AHFCC

4/1997- 9/2001 Associate Chief, Div. Nutritional Carcinogenesis, AHFCC, Valhalla, NY.

1/2001-3/2001 Invited (Health Ministry of Japan) Visiting Scientist, National Cancer Center, Tokyo, Japan.

5/1999-9/2004 Senior Scientist, Div. Nutritional Carcinogenesis & Chemoprevention Program, AHF, Valhalla, NY.

5/1999-10/2001 Professor of Research (Adj.), Dept. of Microbiology, New York Medical College, Valhalla, NY.

6/1996-4/1999 Associate Professor of Research (Adj.), Dept. of Microbiology, New York Medical College, Valhalla, NY.

4/1996-4/1999 Research Scientist, Div. Nutritional Carcinogenesis and Chemoprevention Program, AHF, Valhalla, NY.

4/1994-5/1997 Section Head, Chemoprevention Studies, AHFCC, Div. Nutritional Carcinogenesis and AHF, Valhalla, NY.

1/1991– 9/2004 Member, Chemoprevention Program, AHFCC, AHF, Valhalla, NY.

8/1995-2/1996 Visiting (Associate) Professor, Dutch Atlantis, Saba School of Medicine, Saba Islands.

8/1992-4/1996 Associate Research Scientist, Div. Nutritional Carcinogenesis & Chemoprevention Program, AHFCC, Valhalla, NY.

1/1990-8/1992 Research Associate, Div. of Nutrition and Endocrinology, American Health Foundation Cancer Center, Valhalla, NY.

9/1988-1/1990 Senior Research Fellow, Division of Nutrition and Endocrinology, American Health Foundation Cancer Center, Valhalla, NY.

11/1987-8/1988 Associate Researcher, Department of Microbiology, Osmania University, Hyderabad, India.

01/1984-7/1988 Lecturer (Part-time) for graduate courses (Environmental Microbiology/ Molecular Biology/Immunology), Department of Microbiology, Osmania University, Hyderabad, India. Rao/CV 3

RESEARCH AND SCHOLARSHIP RESEARCH FUNDING: PRESENT (ACTIVE): 1. R01 CA 94962 (2002-2010;-2015) “HMG-R and Polyamine inhibitors for CRC Prevention”. National Cancer Institute, NIH. Total: $1,550,000; Principal Investigator (15% Effort)

2. R01 CA-109247 (2004-2012) “iNOS- and COX-2-Selective Inhibitors for CRC Prevention”. National Cancer Institute, NIH, Total : ~$1,655,000: Principal Investigator (15% Effort).

3. N01-CN-53300 (2005-2011) “Preclinical Efficacy and Intermediate Biomarker Assays” National Cancer Institute, NIH, ~$8,376,000. Principal Investigator (10% Administrative Work Assignment and~40-50% for Scientific efforts on Work Assignments as listed bellow-a-i), To establish multi- center Consortium Program with expertise in the field of Cancer Chemoprevention to carry out preclinical efficacy and intermediate biomarkers assays on potential new generation cancer drugs prior to clinical consideration. (Participating Cancer Centers include: Rutgers, the State University of New Jersey, Georgetown University, Penn State University, MD Anderson Cancer Center, University of Washington and New York University Medical Center).

4. R01-CA 113349 (2007-2012) “Novel Transgenic Animal Models for Colon Cancer Prevention” National Cancer Institute, NIH; Consortium to OUHSC, $80,000 Principal Investigator (3% Effort).

5. N01-CN-35110 (2008-2011) “Combinational Efficacy of Ornithine analogs plus NO-Sulindac for Colorectal Cancer Prevention” Principal Investigator (Effort, 8%).$456,040

6. NCI-RAPID: (2009-2014) Developing Phospho-Ibuprofen for prevention and treatment of pancreatic, colon and bladder cancers. The NCI provides required resources in development phospho-ibuprofen for bulk drug, preclinical toxicology, efficacy, Biomarkers, PK and ADMC; and Phase 0 and I Studies. Principal Investigator

7. R21-CA137482-01 (04/2010 – 03/2012) Pancreatic Stem Cells and Cancer. Role: Co-PI (5% Effort) $425,000

(Current Research Projects from NCI-CN-53300- Dr. Rao’s Laboratory)

a. WA#6-N01-CN-53300 (2006-2010): Efficacy of Potential Chemopreventive Agents in the Transgenic LSL-KRASG12D Pancreatic Cancer Model. Project Leader. C.V. Rao

b. WA#7-CN-53300 (2008-2011): Efficacy of Molecular Targeted Chemopreventive Agents Alone or In combination in the Azoxymethane (AOM)-Induced Colon Cancer Model in Fisher Rats. Project Leader: C.V. Rao

c. WA #8-CN-53300 (2008-2011): Efficacy of Potential Chemopreventive Agents to Prevent Azoxymethane (AOM)-Induced Aberrant Crypt Foci (ACF) In the Colon of Fisher Rats. Project Leader: C.V. Rao

d. WA #11-CN-53300 (2009-2011): Biomarker Modulation By Chemopreventive Agents Alone or In Combination in the Inhibition of (AOM) - Induced Colon Adenocarcinoma in Fisher Rats. PL: C.V. Rao/Co-PL: Dr. Nanjoo Suh Rao/CV 4 e. WA#12-CN-53300 (2009-2011): Efficacy of Molecular Targeted Chemopreventive Agents Alone or In Combination for the Chemoprevention of Lung Cancer Induced by NNK in Female A/J Mice and Female A/J-P53DMUT Mice PL: C.V. Rao. f. WA#13-CN-53300 (2009-2011): Efficacy of Molecular Targeted Chemopreventive Agents alone or in combination in the Transgenic LSL-KRASG12D Pancreatic Cancer Model. PL: C.V. Rao g. WA# 14-CN-53300 (2009-2011): Efficacy of Molecular Targeted Chemopreventive Agents Alone or In Combination in the Azoxymethane (AOM) - Induced Colon Cancer Model in Fisher Rats . PL: C.V. Rao h. WA# 15-CN-53300 (2009-2011): Efficacy of Molecular Targeted Chemopreventive Agents Alone or In Combination for the Chemoprevention of Urinary Bladder Cancer in SV40T-Uroplakin II Transgenic Mice. PI: C.V. Rao i. WA# 17-CN-53300 (2010-2011): Efficacy of Farnesyl/geranyl-pyrophosphate modulators against the Rodent Models of colon and pancreatic cancers. PL: C.V. Rao j. WA#18-CN-53300 (2010-2011): Modulation of Colonic Cancer Stem (Tumor Initiating) Cells by Potential Chemopreventive Agents Alone or In Combination in the Azoxymethane (AOM)-Induced Colon Carcinogenesis in Fisher Rats. PL: C.V. Rao

PENDING: 1. 1R01 149921A1 “Chemoprevention of colon cancer by dual 5-LOX/COX-selective inhibitors” Principal Investigator. Pending.

PAST/COMPLETED (RESEARCH FUNDING): 1. RO1-CA-37663-13 (2003-2009) Co-Principal Investigator. “COX-2 Inhibitor and n-3 PUFA in Colon Cancer Prevention”. National Cancer Institute, NIH. Total awarded $1,645,500.

2. P20 CA 97943-03 (2002-2009) “Cancer Center Planning Grant” NCI, NIH, Program Leader/Director, Cancer Chemoprevention Program. (10% Effort) Total: $1,675,500

3. N01-CN-53300: WA #2: (2005-2009) Efficacy of potential chemopreventive agents to prevent AOM-induced aberrant crypt foci (ACF) in the colon of F344 rats. PI: C.V. Rao. Total awarded: $467,850.

4. N01-CN-53300: WA #3: (2005-2009) Efficacy of potential chemopreventive agents alone or in combination in the azoxymethane (AOM)-induced colon cancer model in Fisher rats. PIs: Dr. C.V. Rao and Dr. B. S. Reddy: Total awarded $472,900

5. R01 CA 80003-09 (1998-2007 Principal Investigator) “Mechanisms for Chemoprevention of Colon Cancer”. National Cancer Institute, NIH. Total : $1,225,000 (years 5-9)

6. N01 CN-43308C (2005-2007) Principal Investigator “Combination of Chemopreventive Agents in Rat Model of Colon Cancer”., National Cancer Institute, NIH. Total $257,890 Rao/CV 5

7. N01 CN 25114, (2002-2005) Principal Investigator. “Developing selective target inhibitors (COX-2, ER, VEGF, p53 modulators, beta-Catenin regulators) alone or in combination against colon cancer using the rat colon tumor model”. National Cancer Institute, NIH, Total $458,328.

8. N01-CN-05112 (2001-2004) Principal Investigator, “Developing selective target inhibitors (RXR-, ER-, EGFR-, PPAR-, FPTase) against colon cancer using the rat colon tumor model”. National Cancer Institute, NIH, Total $495,000.

9. N01-CN-15122 (2001-2004) Principal Investigator “Developing nitric oxide-releasing NSAIDs for colon cancer prevention and treatment”. National Cancer Institute, NIH, Total $425,500.

10. P01 CA 46589 (1988-1992; 1993-1998; 1998-2003) Project #2 Leader & Bioassay Core Director (From 1992-2003) “Chemoprevention of Cancer by Organoselenium Compounds”. National Cancer Institute, NIH. This P01 Grant has been successfully funded for 16 years. (Total over $24.5 million).

11. R01 CA 37663, Co-Investigator (1991-1994, $678,550); Co-Principal Investigator, (1995-1998, $736,500; 1998-2002, $854,600) “Types and Amount of Dietary Fat and Colon Cancer’. Resubmitted in 2003 in different title. (See above as #1).

12. N01 CN 95031 (1999-2001), Principal Investigator. “Developing Lipoxyganse Inhibitors for Colon Cancer Prevention-AOM-Rat Model” National Cancer Institute, NIH, Total $345,380.

13. P30 CA 17367 (1998), Seed Grant, Principal Investigator, “Type-2 series cyclopentonone PGs in colon tumor promotion”. NCI, NIH, Total $15,000.

14. N01 CN 75027 (1997-2000), Principal Investigator, “Pharmacokinetic Studies on Selective Chemopreventive Agents in Experimental Animals” NCI, NIH, Total $328,250.

15. P30 CA 17367 (1996), Seed Grant, Principal Investigator “Development of Nitric -Oxide inhibitors for Colon Cancer Prevention and Treatment” NCI, NIH, Total $12,000.

16. N01 CN 65119 (1996-1999), Co-Principal Investigator, “Effect of potential chemopreventive agents on azoxymethane-induced colon cancer in rats”. NCI, NIH, Total $495,500.

17. R01 CA 60904 (1994-1998), Principal Investigator, “Chemoprevention of Colon Cancer by Cinnamic Acid Esters” NCI, NIH, Total $ 878,300.

18. N01 CN 65108 (1995-1998), Principal Investigator, “Chemopreventive Drug Screening and Development in Animal Models of Colon Cancer” NCI, NIH, Total $ 488,500.

19. CNE 86434 (1992-1995), Principal investigator, “Structure Activity and Mechanistic Studies on PEC-analogs” ACS, Total, $350,000.

20. N01 CN 85112 (1993-1996), Co-Principal Investigator, “Chemoprevention of AOM-induced colon cancer in rats by a combination of chemopreventive agents. NCI, NIH, Total $ 429,000.

21. N01 CN 95153 (1994-1996), Co-Principal Investigator, “Chemoprevention of colon cancer with selective agents “. NCI, NIH, Total $ 356,500.

22. N01 CN 85095 (1992-1995), Co-Principal Investigator, “Chemoprevention of colon cancer in rats with selected polyamine synthesis inhibitors and isothiocyanates” NCI, NIH, Total, $398,600. Rao/CV 6

23. AHF (1993), Seed Grant, Principal Investigator, “Role of secondary bile acids on the induction of COX-2 and 12-LOX in rat AOM-model”. Total $6,000.

24. N01 CN 85097 (1992-1995), Co-Principal Investigator, “Chemoprevention of PhIP-induced colon cancer in rats with selected chemopreventive agents” NCI, NIH, Total, $475,000.

25. N01 CN 85096 (1991-1994), Co-Principal Investigator, “Studies of Natural Inhibitors of Chemical Carcinogenesis” NCI, NIH, Total, $422,500.

26. P30 CA 17367 (1991), Principal Investigator, “Potential role of phytochemicals for colon cancer prevention”. NCI-Seed Grant, NIH, Total $12,500.

27. N01 CN 85090 (1990-1992), Co-Investigator, “Effect of Chemopreventive agents Piroxicam & DFMO on Intermediate Biomarkers induced by AOM”. NCI, NIH, Total $455,000.

28. N01 CN 45191 (1989-1991), Co- Investigator, “Chemoprevention of colon cancer by combination of ellagic acid, Oltipraz, piroxicam, DFMO and DHEA-analog” NCI, NIH, Total, $579,000.

INDUSTRIAL FUNDING (Partial List)

1. AHF-637 (2000-2003) Monsanto, Principal Investigator, “Development of sea-gold fatty acids for colon cancer prevention” Total $ 126,000.

2. AHF-635 (1998-2000) Monsanto, Principal Investigator, “Development of gamma-tocopherol for colon cancer prevention” Total $ 75,000.

3. AHF-628 (1997-1998) RWJ Pharmaceutical Research Foundation, Principal Investigator, “Development of COX-2 Inhibitor (JW-522) for colon cancer prevention and treatment” Total $ 48,000.

4. AHF-618 (1995-1997) Searle, Principal Investigator, “Development of celecoxib efficacy in colon adenocarcinoma model”. Total $ 286,000.

5. AHF-616 (1997-1999) Kraft General Foods, Principal Investigator, “Prevention of colon cancer by wheat-bran fractions’, Total $ 185,000.

6. AHF-598 (1997-1998) North Carolina Dairy (Rhodia, Inc.), Principal Investigator, “Potential colon cancer preventive properties of Lactobacillus NCFM” Total, $65,000.

7. AHF-618 (1994-1996) Searle, Principal Investigator, “Development of COX-2 selective inhibitors for colon cancer prevention and treatment”. Total $98,500.

8. AHF-576 (1994-1996) Morinaga, Co-Principal Investigator, “Effect of Bifidobacterium longum on AOM-induced colon carcinogenesis” Total, $184,800.

9. AHF-565 (1992-1994) Kraft General Foods, Principal Investigator, “Prevention of colon cancer by coffee-fiber”. Total $ 56,000.

10. AHF-565 (1991-1993) Kraft General Foods, Principal Investigator, “Prevention of colon cancer by Bifido-factors”. Total $ 56,000. Rao/CV 7

RESEARCH INTERESTS: Overall Research Focus Molecular and Preclinical Approaches to Prevention of Colorectal and other Aero-digestive Tract Cancers: Research in my lab is focused on cancer chemoprevention with major goal to design and develop efficacious strategies for clinical prevention of colorectal cancer and other aero-digestive tract cancers. Current efforts focus on identifying optimal molecular targets for chemopreventive drug development and understanding the molecular mechanisms involved in the pathology of colorectal, pancreas and lung cancers.

Areas of Research:

I) Molecular targeted approaches for cancer drug development. A major focus of laboratory has been identification of proper molecular targets for major epithelial cancers (colon, pancreas, and lung); and develop selective small molecules that effective chemopreventive agents and their regimens for chemoprevention of cancer using in vitro and in vivo models.

II) Exploring the mechanisms by which chemopreventive agents inhibit epithelial tumorigenesis. Mechanistic studies, utilizing a wide-array of technologies, in vitro (differential expression systems) and in vivo (chemically-induced and transgenic knock-In and knock-out) models to examine cancer chemopreventive mechanisms.

III) Understanding the role of gene-nutrient interactions in colorectal and lung carcinogenesis. Exploring mechanisms by which the composition of dietary fatty acids influences the progression of tumors of the colon and the lungs.

IV) Establishing biomarkers (molecular targets) relevant to different stages of colon carcinogenesis i.e., aberrant crypt foci, adenoma and adenocarcinoma; utilizing these biomarkers as surrogate endpoints of the specific stages. V) Another major focus is understanding role of genomic instability in epithelial cancer development using in vivo models of chromosomal instability.

PUBLICATIONS: (~173) (Refereed Journals 155); (Non-refereed + book Chapters*, 18+): Refereed Citations, >8,600; Articles with Citation data for 111 articles, Average Citations/Article: 76.7; h-index: 43) and over 7,500 web Citations)

1. Patlolla, J.M. and Rao, C.V. (2011) Triterpenoids for cancer prevention and treatment: Current status and future prospectives. Curr. Pharmaceut. Biotechn., 8: (s1-s12) In press 2. Rao, C.V., Kajiwara, AK, and Kawamori, T. (2011) Prevention of multiple adenomatous polyp development in APCmin mice by -3 fatty acid-rich perilla oil. Int. J Cancer., In press 3. Mohammed, A, Janakiram N.B, Li Q, Madka V, , Ely M, Lightfoot S, Crawford H, Steele V.E., and Rao C.V. (2010) EGFR inhibitor gefitinib prevents progression of pancreatic lesions to carcinoma in a conditional LSL-K-rasG12D/+ transgenic mice model. Cancer Prev. Res., 3:1417- 1426. Rao/CV 8

4. Yamada, H.Y, and Rao, C.V. (2010) Genes that modulate the sensitivity for anti-microtuble drug-mediated chemotherapy. Curr. Cancer drug Targets., May 21. 5. May, R., Sureban, S.M, Lightfoot, S.A, Brackett, D.J, Postier, R.G, Whche, J.H, Rao, C.V., Anant, S, and Houchen, C.W. (2010) Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. Am J. Physiol. Gastrointest. Liver Physiol. 299: G303-G310

6. Janakiram NB, Mohammed A, Zhang Y, Choi CI, Woodward C, Collin P, Steele VE, Rao CV. (2010) Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth. Cancer Prev Res., 3: 82-19. 7. Rao CV, Cohen L, El-Bayoumy K. (2009) Bandaru S. Reddy: in memoriam (1930-2009). Nutr. Cancer. 61: 903-905. 8. Rao CV, Steele VE, Stoner GD, Conney AH (2009) Bandaru s. Reddy: in memoriam (1930-2009), Cancer Prev Res, 2:912-3. 9. Steele VE, Rao CV, Zhang Y, Patlolla J, Boring D, Kopelovich L, Juliana MM, Grubbs CJ, Lubet RA. (2009) Chemopreventive efficacy of naproxen and nitric oxide-naproxen in rodent models of colon, urinary bladder, and mammary cancers . Cancer Prev Res, 2:951-6. 10. Rao, C.V., Steele, V.E., Swamy, M.V., Patlolla, J., Guruswamy, S., Kopelovich, L. (2009) Inhibition of AOM-induced colorectal cancer by CP-31398, a TP modulator, alone or In combination with low doses of celecoxib in male F344 rats. Cancer Res., 69 :8175-82 11. Guruswamy, S. and Rao, C.V. (2009). Synergistic effects of lovastatin and celecoxib on caveolin-1 and its down-stream signaling molecules: Implications for colon cancer prevention. International J. Oncology , 35: 1037-47. 12. Yamada, H.Y., and Rao, C.V. (2009) “Brd8 is a chemosensitizing target for spindle poisons in colorectal cancer therapy” International Journal of Oncology. 35:1101-9 13. Rao, C.V., Yamada, H.Y., Dai, W. (2009) Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segreatation: a perspective from genetic studies in mice. Carcinogenesis. 30:1469-74. 14. *Raju, Jayadev, and Rao, C. V. (2009) “Fenugreek (Diosgenin)”. Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine. Ed. Aggarwal, Bharat B. and Kunnumakkara, Ajaikumar B. 173-196 15. Mandal M.N., Patlolla J.M., Zheng L., Agbaga M.P., Tran J.T., Wicker L., Kasus-Jacobi A., Elliott M.H., Rao, C. V., Anderson R.E. (2009) Curcumin protects retinal cells from light- and oxidant stress-induced cell death. Free Radic Biol Med.: 46(5): 672-679 16. Janakiram, N.B., Rao, C.V. (2009) Role of lipoxins and resolvins as anti-inflammatory and proresolving mediators in colon cancer. Current Molecular Medicine. 9(5): 565-579 17. Janakiram, N.B., Steele, V.E., Rao, C.V. (2009) Estrogen Receptor-β as a potential target for colon cancer: Prevention of azoxymethane-induced colon carcinogenesis by raloxifene in F344 Rats. Cancer Prev. Res. 2: 52-59. (Cover page Illustration) 18. Rao, C.V., Malisetty, V.S., Patlolla, J.M.R., Kopelovich, L. (2008) Supression of Familial Adenomatous Polypois by CP-31398, a TP53 modulator, in APCmin/+ Mice. Cancer Res. 68: 7670-7675. Rao/CV 9

19. Rao, C.V., Joseph, S., Gao, L., Patlolla, J., Choi, C., Kopelovich, L., Steele, V.E., Rigas, B. (2008) Pharmacokinetic and Pharmacodynamic study of NO-ASA in F344 rats. Int. J. Oncol. 33(4):799-805 20. Malisetty, S.V., Alta, M., Patlolla J., Zhang, Y., Rao, C.V. (2008) Prevention and treatment of pancreatic cancer by curcumin in combination with Omega-3 fatty acids. Nutr. Cancer 60:1:81-9. 21. Rigas B, Rao CV, Cooney R, Singh S. (2008) Food components, alternative medicine, and cancer: progress and promise. Nutr Cancer. 60: 1-2 22. Guruswamy S., Malisetty, V.S., Choi, C., Steele, V.E., Rao, C.V. (2008) S-adenosyl L- methionine inhibits azoxymethane-induced colonic aberrant crypt foci in F344 rats and suppresses human colon cancer Caco-2 cell growth in 3D culture. Int. J. Cancer: 122,25-30 (2008). (Cover page Illustration) 23. Janakiram N.B, Cooma, I, Malisetty V.S., Jagan, P, Steele V. E, and Rao C.V. (2008) Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells. Pharm Res. 25:, 2151-57 24. Janakiram, N. B, Cooma, I., Mohammed, A., Steele, V.E., Rao, C.V. (2008) -Ionone inhibits colonic aberrant crypt foci formation in rats, suppresses cell growth and induces retinoid X receptor-α in human colon cancer cells. Mol Cancer Ther. 7: 181-190. 25. Guruswamy, S., Rao, C.V. (2008) Multi-Target Approaches in Colon Cancer Chemoprevention Based on Systems Biology of Tumor Cell-Signaling. Gene Reg and Sys Biol. 2008:2 1-14. 26. Janakiram, N.B., and Rao, C.V. (2008) Molecular markers and targets for colorectal cancer prevention. Acta Pharmacol Sin. 29 (1): 1-20. (Cover page Illustration)

27. Rao, C.V. (2007) Regulation of COX and LOX by curcumin. Adv Exp Med Biol. 2007;595:213- 26. Review 28. Rao, C.V. (2007) Naturally-occurring anti-inflammatory agents for chemoprevention of colon cancer” Cancer; Disease progression and Chemoprevention. 37: 91-107. 29. Rao, C.V. (2007) Regulation of COX and LOX by curcumin and its analogs. Expert. Opin. Ther. Targets; Pages: 213-229. 30. Swamy, M.V., Patlolla, J.M, Steele, V.E., Kopelvich, L., Reddy, B.S., and Rao, C.V. (2006) Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice. Cancer Res. 15;66(14):7370-7. 31. Rao C.V., Reddy BS, Steele VE, Wang CX, Liu X, Ouyang N, Patlolla JM, Simi B, Kopelovich L, Rigas B. (2006) Nitric oxide-releasing aspirin and indomethacin are potent inhibitors against colon cancer in azoxymethane-treated rats: effects on molecular targets. Mol Cancer Ther., 5(6):1530-1538. 32. Reddy, B.S., Wang, C-X., Kong, A-N., Steele, V.E., Kopelvich, L., and Rao, C.V. (2006) Prevention of azoxymethane-induced colon cancer by combination of low-doses of atorvastatin, aspirin and celecoxib in F344 rats. Cancer Res. 66: 4542-4546. Rao/CV 10

33. Patlolla, J.M., Raju, J., Malisetty, V.S., and Rao, C.V. (2006) -Escin inhibits colonic aberrant crypt foci formation in rats and regulates the cell cycle growth by inducing p21waf1/cip1 in colon cancer cells. Molecular Cancer Therapeutics, 5: 1459-1466. 34. El-Bayoumy K, Das A, Narayanan B, Narayanan N, Fiala ES, Desai D, Amin S, Rao CV and Sinha R. (2006) Molecular targets of the chemopreventive agent 1,4- phenylenebis(methylene)selenocyanate in human non small cell lung cancer. Carcinogenesis, 26: 420-427. 35. Reddy, B.S. and Rao, C.V. (2005). Chemoprophylaxis of colon cancer. Curr. Gastroent. Rep., 7: 389-395. 36. Reddy, B.S., Patlolla, J.M., Simi, B., Wang, S.H., Rao, C.V. (2005) Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in n-3 polyunsaturated fatty acids. Cancer Res., 65: 3245-51. 37. Rao, C.V., Yang, Y.M., Swamy, M.V., Liu, T., Fang, Y, Mahmood, Jhanwar-Uniyal, m., and Dai, W. (2005) Colonic tumorigenesis in BubR1+/-Apcmin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. Proceed. Natl. Acad. Sci., USA, 102: 4365-4370. 38. Rao, C.V., Cooma, I., Simi, B., Swamy, M.V., and Reddy, B.S. (2005) Modulation of inducible NOS and COX activities by curcumin during different stages of experimental colon carcinogenesis. Int. J. Oncology, 24: 943-949. 39. Reddy, B.S., Semi, B., Patlolla, J.M., and Rao, C.V. (2005) Prevention of colon cancer by very low doses of COX-2 inhibitor combined with omega-3 fatty acid rich diet. Cancer Res. 65: 8022-8028. 40. Rao, C.V. (2005) Multiagent regimens for colon cancer chemoprevention, ASCO, Educational series, 41: 129-134. 41. Jayadev Raju, Malisetty, V Swamy, Cooma, I, Jagan M.R. Patlolla, Reddy, B.S., Steele, V.E. and C. V. Rao. (2005) Low doses of beta-carotene and lutein inhibit AOM-induced rat colonic ACF formation but high doses augment ACF incidence. Int J Cancer. 113: 798-802. 42. Rao, C.V. (2004) Nitric oxide signaling in colon cancer chemoprevention. Mutat. Res, 555: 107-119. 43. Wai Dai, Qi Wang,Tongyi Liu, Malisetty V. Swamy, Yuqiang Fang, Suqing Xie, Radma Mahmood, Yangming Yang, Ming Xu, and C. V. Rao. (2004). Slippage of mitotic arrest and enhanced tumor development in mice with BUBR1 haploinsufficiency. Cancer Res., 64: 440- 445. Cancer Research –Cover page Illustration). 44. Herzog, C. R., Malisetty, V. S., and Rao, C. V. (2004) Reply To Correspondence: Axel Schonthal Ref: M.V. Swamy, et al. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Research, 64: 2937-2938. 45. Jayadev Raju, Jagan M.R. Patlolla, Malisetty V. Swamy and C. V. Rao. (2004) Colon cancer preventive effects of Trigonella foenum graecum (fenugreek) seed and its constituent diosgenin in vivo and in vitro. Cancer Epidemiology Biomarkers and Prevention, 13:1392-1398. Rao/CV 11

46. Patlolla, J.M.R. Malisetty, V. S., and Rao, C.V. (2004) Up-regulation of Caveolin-1 in experimental colon carcinogenesis and human colon cancer cell lines. Oncol. Rpt., 11: 957- 963. 47. Malisetty V. Swamy, Indranie Cooma, J.M.R. Patlolla, Barbara Simi, Bandaru S. Reddy and Rao, C. V. (2004) Modulation of COX-2 activities by the combined action of celecoxib and docosahexanoic acid: novel strategies for colon cancer prevention. Molecular Cancer Therapeutics, 4,: 215-221. 48. Rao, C.V. NSAIDs and Chemoprevention-Review. Current Cancer Drug Targets, 4, 29-42, 2004 49. Rao, C.V., Steele, V.E., Cooma, I., Kelloff, G.J., and Reddy, B.S. (2004) Modulation of colonic aberrant crypt foci development by COX-1 and COX-2 selective inhibitors. Onco Reports, 10: 876-882. 50. Malisetty, V. S., Herzog, C. R., and Rao, C. V. (2003) Celecoxib inhibition of COX-2 in colon cancer cell lines increases the nuclear localization of functionally active p53. Cancer Res.63: 5239-5242. 51. Rao, C.V. (2003) Do Irradiated Foods Cause or Promote Colon Cancer? Nutrition &. Cancer, 46: (2), 65-68. 52. Reddy, B.S., and Rao, C.V. (2003) Chemoprevention of colon cancer by curcumin. In: Phytochemical: Mechanisms of Action. CRC Press, 177-192, 2003. 53. Reddy, B.S. and Rao, C.V. (2003) Chemoprevention of Cancer by Curcumin. In: (Kelloff, G.J., Hawk, E.T., Segman, CC., eds.) Cancer Chemoprevention Vol. #1. Promising Cancer Chemopreventive Agents. The Humana Press Inc., 135-143, 2003 54. Rao, C.V. and Reddy, B.S. (2003) Role of synthetic and naturally occurring cyclooxygenase inhibitors in colon cancer prevention. In COX-2 Blockade in Cancer Prevention and Therapy. Ed: R.E. Harries, Humana Press Inc., Totowa, NJ. Pp. 71-83. 55. Rao, C.V., Newmark, H.L., and Reddy, B.S. (2002) Chemopreventive effect of farnesol and lanosterol on colon carcinogenesis. Cancer Detection & Prevention, 26: 419-425. 56. *Reddy, B.S., Hirose, Y., and Rao, C.V. (2002). Types of dietary fat and colon cancer risk. In: Exogenous Factors in Colonic Carcinogenesis. (Scheppach, W., and Scheurlen, M. eds.) Kluwer Academic Press. pp. 120-127. 57. Reddy, B.S., and Rao, C.V. (2002) Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J. Environmental Pathol. Toxicol. Oncol., 21: 155-164. 58. Steele, V.E., Boone, C.W., Dauzonne, D., Bensasson, R. and Rao, C.V. (2002) Correlation between electron-donating ability of a series of 3-nitroflavones and their efficacy to inhibit the onset and progression of aberrant crypt foci in the rat colon. Cancer Res., 62: 6506-6509. 59. El-Bayoumy, K., Rose, D., Papanikolaou, N., Leszczynska, J., Swamy, M.V., and Rao, C.V. (2002) Cyclooxygenase-2 expression influences the growth of human large and small cell lung carcinoma lines in athymic mice: Impact of an organoselenium compound on growth regulation. Int. J. Oncol., 20: 557-561 60. Rao, C.V., Cooma, I., Simi, B., Manning, P.T., Connor, J.R., and Reddy, B.S. (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon Rao/CV 12

carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res., 62: 165-170. 61. Swamy, M.V., Cooma, I., Reddy, B.S. and Rao, C.V. (2002) Lamin B, caspase-3 activity, and apoptosis induction by a combination of HMG-CoA reductase inhibitor and COX-2 inhibitors: A novel approach in developing effective chemopreventive regimens. Int. J. Oncol., 20: 753-759. 62. Dai, W., Liu, T., Wang, Q., Reddy, B.S., and Rao, C.V. (2002) Down-regulation of PLK3 gene expression by types and amount of dietary fat in rat colon tumors. Int. J. Oncol., 20: 121-126. 63. Rao, C.V., Wang, C-Q., Simi, B., Jose, R.G., Cooma, I., El-Bayoumy, K. and Reddy, B.S. (2001) Chemoprevention of colon cancer by a glutathione conjugate of 1,4- phenylenebis(methylene)selenocyanate, a novel organoselenium compound with low toxicity. Cancer Res., 61: 3647-3652 64. El-Bayoumy, K., Rao, C.V., and Reddy, B.S. (2001) Multi-organ sensitivity to anticarcinogenesis by the organoselenium 1,4-phenylenebis(methylene)selenocyanate., Nutr. Cancer., 40: 18-27. 65. Rao, C.V., Reddy, B.S., Semi, B., and Newmark, H (2001). Induction of apoptosis in colon cancer cells by farnesol and lanosterol and their potential chemopreventive properties in rat colon carcinogenesis. Cancer Detect Prev.; 24(6):219-25. 66. Hirose, Y., Rao, C.V., and Reddy, B.S. (2001) Modulation of inducible nitric oxide synthase (iNOS) expression in rat intestinal cells by colon tumor promoters. Int. J. Oncology, 18: 141- 146. 67. Rao, C.V., Hirose, Y., Cooma, I., and Reddy, B.S. (2001) Modulation of experimental colon tumorigenesis by types and amounts of dietary fatty acids. Cancer Res., 61: 1927-1933. 68. Chung, F-L., Conaway, C.C., Rao, C.V., and Reddy, B.S. (2000) Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate. Carcinogenesis, 21: 2287-2291. 69. Rao, C.V., Cooma, I, Simi, B., Rosa, R., El-Bayoumy, K., and Reddy, B.S. (2000) Chemoprevention of familial adenomatous polyposis development in the APCmin mouse model by 1,4- phenylenebis(methylene)selenocyanate. Carcinogenesis 21: 617-621. 70. Reddy, B.S., Hirose, Y., Lubet, R., Steele, V.E., Kelloff, G., Paulson, S., Seibert, K., and Rao, C.V. (2000) Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res., 60: 293-297. 71. Rao, C.V., Simi, B., Hirose, Y., Upadhyaya, P., El-Bayoumy, K., and Reddy, B.S. (2000) Mechanisms in the chemoprevention of colon cancer: Modulation of protein kinase C, tyrosine protein kinase, and diacylglycerol kinase activities by 1,4-phenylenebis- (methylene)selenocyanate and impact of low-fat diet. Int. J. Oncol., 16: 519-527. 72. Reddy, B.S., Hirose, Y., Lubet, R., Steele, V.E., Kelloff, G., and Rao, C.V. (2000). Lack of chemopreventive efficacy of DL-selenomethionine in colon carcinogenesis. Int. J. Mol. Med., 5: 327-330. 73. Hirose, Y., Rao, C.V., and Reddy, B.S. (2000) Modulation of inducible cyclooxygenase (COX-2) and nitric oxide synthase (iNOS) expression in rat intestinal cells by colon tumor promoters. Int. J. Oncology, 17: 131-136. Rao/CV 13

74. *Reddy, B.S. and Rao, C.V. (2000) Colon cancer: a role for cyclooxygenase-2 specific nonsteroidal anti-inflammatory drugs. Drugs & Aging, 16: 329-334, 75. Reddy, B.S., Hirose, Y., Cohen, L.A., Simi, B., Cooma, I., and Rao, C.V. (2000). Preventive potential of wheat bran fractions against experimental colon carcinogenesis: Implications for human colon cancer prevention. Cancer Res., 60: 4792-4797. 76. Agrawal AK, Rao CV, Sairam K, Joshi VK, Goel RK. (2000) Effect of Piper longum Linn, Zingiber officianalis Linn and Ferula species on gastric ulceration and secretion in rats. Indian J Exp Biol. 38:994-8. 77. Reddy, B.S., Kawamori, T., Lubet, R., Steele, V.E., Kelloff, G.J., and Rao, C.V. (1999) Chemopreventive effect of sulindac sulfone against colon cancer depends on time of administration during the carcinogenesis process. Cancer Res., 59: 3387-3391. 78. Reddy, B.S., Kawamori, T., Lubet, R., Steele, V.E., Kelloff, G.J., and Rao, C.V. (1999) Chemopreventive effect of S-methyl methane thiosulfanate and sulindac administered together during the promotion /progression stages of colon carcinogenesis. Carcinogenesis, 20: 1645-1648. 79. Rao, G.V., Rao, C.V., and Reddy, V.S. (1999) Perceptions on effects of environmental pollutants in Hyderabad city. Indian J. Public Health., 43: 67-70. 80. Rao, C.V., Sanders, E.M., Cooma, I, Simi, B., and Reddy, B.S. (1999) Prevention of colonic preneoplastic lesions by probiotic Lactobacillus acidophilus NCFMTM in male F344 rats. Int. J. Oncol., 14: 939-944. 81. Agarwal, B., Rao, C.V., Ramey, W.R., Reddy, B.S., and Holt, P. (1999) Lovastatin augments sulindac-induced apoptosis and chemopreventive activity against colon cancer. Gastroenterology., 117: 838-847. 82. Rao, C.V., Kawamori, T., Hamid, R., and Reddy, B.S. (1999) Chemoprevention of colon carcinogenesis by inducible nitric oxide synthase selective inhibitor. Carcinogenesis, 20, 641- 646.

83. Rao, C.V, Agarwal B, Bhendwal S, Ramey WR, Shirin H, Reddy BS, Holt PR (1999). Statins augments nonsteriodal anti-inflammatory drug-induced apoptosis in colon cancer cells and potential for combinational chemoprevention. Cancer Res., 59:838-47. 84. Rao, C.V., Wang, C-X, Lubet, R., Kelloff, G.J. and Reddy, B.S. (1999) Experimental colon tumor suppression by carboxyamido-triazole (L651582), a selective signal transduction inhibitor. Int. J. Mol. Med, 4: 112-119. 85. Rao, G.V., Reddy, V.S., and Rao, C.V. (1999) Perceptions on effects of environmental pollutants in Hyderabad City.Indian J Public Health. 43(2):67-70. 86. Kawamori, T., Lubet, R., Steele, V.E., Kelloff, G.J., Kaskey, R.B., Rao, C.V., and Reddy, B.S. (1999) Chemopreventive effect of curcumin, a naturally-occurring anti-inflammatory agent, during the promotion and progression stages of colon cancer. Cancer Res., 59: 597-601. 87. Rao, C.V., Chou, D., Simi, B., Ku, H., and Reddy, B.S. (1998) Prevention of colonic aberrant crypt foci and modulation of large bowel microbial activity by coffee fiber, inulin and pectin. Carcinogenesis, 19:1815-1819. Rao/CV 14

88. Sonde, V.D., Tarapore, R., Sinkar, P., Rao, C.V., Krishnan, S. (1998) Simultaneous administration of diethylphthalate and ethyl alcohol and its toxicity in male SD rats. Env. Toxicol., 19:23-29. 89. Kawamori, T., Rao, C.V., Seibert, K., and Reddy, B.S. (1998) Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res., 58: 409-412. 90. Rao, C.V., Newmark, H.L., and Reddy, B.S. (1998) Chemopreventive effect of squalene on colon cancer. Carcinogenesis, 19:287-290. 91. Subrahmanyam D, Renuka B, Rao CV, Sagar PS, Deevi DS, Babu JM, Vyas K. (1998) Novel D-ring analogues of podophyllotoxin as potent anti-cancer agents. Bioorg Med Chem Lett.;8(11):1391- 6. 92. Kawamori, T., El-Bayoumy, K., Rosa, J.G., Rao, C.V. and Reddy, B.S. (1998) Evaluation of benzyl selenocyanate glutathione conjugate for potential chemopreventive properties in colon carcinogenesis. Int. J. Oncol., 13:29-34. 93. Singh, J., Hamid, R., Rao, C.V. and Reddy, B.S. (1998) Dietary fish oil inhibits the expression of farnesyl protein transferase and colon tumor development in rodents. Carcinogenesis, 19: 985- 989. 94. Rao, C.V., Wang, C-X., Simi, B., Steele, V. and Reddy, B.S. (1997) Enhancement of experimental colon cancer by genistein. Cancer Res. 57:3717-3722. 95. Reddy, B.S., Hamid, R. and Rao, C.V. (1997) Effect of dietary oligofructose and inulin on colonic preneoplastic aberrant crypt foci inhibition. Carcinogenesis, 18: 1371-1374. 96. Samaha, H., Hamid, R., El-Bayoumy, K., Rao, C.V. and Reddy B.S. (1997) The role of apoptosis in the modulation of colon carcinogenesis by dietary fat and by the organoselenium compound 1.4-phenylenebis(methylene)selenocyanate. Cancer Epidemiol. Biomarkers & Prev., 6:699-704. 97. Rao, C.V. and Reddy, B.S. (1997) Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5- b]pyridine-induced lymphoma formation by oltipraz. Correspondence: Cancer Res., 57: 2806- 2807. 98. Samaha, H., Kelloff, G.J., Steele, V., Rao, C.V., Reddy, B.S. (1997) Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate and 6-phenylhexyl isothiocyanate: Apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res., 57:1301- 1305. 99. Challa, A., Ramakrishna, D. Rao, C.V., and Reddy, B.S. Interactive suppression of aberrant crypt foci induced by azoxymethane in the rat colon by phytic acid and green tea. Carcinogenesis, 18: 2023-2026, 1997 100. Reddy, B.S., Rivenson, A., El-Bayoumy, K., Upadhyaya, P., Pittman, B. and Rao, C.V. (1997) Chemoprevention of colon cancer by organoselenium compounds and impact of high- and low- fat diets. JNCI, 87: 506-512. 101. Reddy, B.S., Rivenson, A., Samaha, H, Steele, V. and Rao, C.V. (1997) Chemoprevention of colon cancer by Perilyll alcohol. Cancer Res., 57:420-425. 102. Rao, C.V. and Rivenson, A (1997) Immunocytochemical localization of epidermal growth factor receptor and cyclooxygenase-1 &2 in chemically-induced rat colonic tumor. J Exp. Pathol., 82:2756-62. Rao/CV 15

103. Singh, J., Rivenson, A., Tomita, M., Rao, C.V., Shimamura, S., Ishibasi, N., and Reddy, B.S. Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis, 18: 833-841, 1997. 104. Rao, C.V., Rivenson, A., Zang, E., Steele, V., Kelloff, G., and Reddy, B.S. (1996) Inhibition of 2- amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced lymphoma formation by oltipraz. Cancer Res., 56:3395-3398. 105. Rao, C.V., Rivenson, A. E., Steele, V., Kelloff, G., and Reddy, B.S. (1996) Inhibition of 2-amino-1- methyl-6-phenylimidazo[4,5-b]pyridine-induced mononuclear leukemia by oltipraz, a dithiole- 3-thione male F344 rats. Mol. Carcinogenesis ., 4:654-659. 106. Rao, C.V., Semi, B., Kawamor, T., and Reddy, B.S. (1996) Suppression of azoxymethane-induced colonic arachidonate metabolite formation in male F344 rats by ascorbylpalmitate and carbenoxolone, Appl. Pharma. 18:199-204. 107. Reddy, B.S., Rao, C.V., and Seibert, K. (1996) Evaluation of cyclooxygenase-2 Inhibitor for potential Chemopreventive properties in colon cancer. Cancer Res., 56:4566-4569. 108. El-Bayoumy, K., Prokipczyk, B., Peterson, L.A., Rao, C.V., Desai, D., Amin., A., Reddy, B.S., Hoffmann, D., and Wynder, E. (1996) Effects of dietary fat content on the metabolism of 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and on DNA-methylation induced by NNK. Nutrition and Cancer, 26: 1-10.. 109. Reddy, B.S. and Rao, C.V. (1996) Micronutrients as chemopreventive agents. In: Principles of Chemoprevention, B.W. Stewart, D. McGregor, and P. Kleihues, (eds.), Publication No. 139, pp. 221-235. 110. Rao, C.V., Simi, B., Wynn, T.T., Garr, K., Reddy, B.S. (1996) Modulating effect of amount and types of dietary fat on colonic mucosal PLA2, PI-PLC activities and COX metabolite formation during different stages of colon tumor promotion in male F344 rats. Cancer Res., 56:532-537. 111. Reddy B.S., Simi, B., Patel, N., Aliaga, C., and. Rao, C.V. (1996) Effect of amount and types of dietary fat on intestinal bacterial 7-hydroxylase and PI-PLC, and colonic mucosal DAG kinase and PKC activities during different stages of colon tumor promotion . Cancer Res., 56:2314- 2320. 112. Rao, C.V., Semi, B, and Rigotty, J. (1996). Enhancement of azoxymethane-induced colonic cyclooxygenase-2 expression and activity by deoxycholic acid in rats. Mol. Carcinogenesis, 3: 247-252. 113. Holt, P.R., Mokuolu, A., O., Distler, P., Rao, C.V., Liu, T., Reddy, B.S. (1996) Regional distribution of carcinogen-induced colon neoplasia in the rat. Nutrition Cancer, 25: 129-135. 114. Reddy, B.S., Wynn, T.T., Upadhyaya, P, Rao, C.V. (1996) Evaluation of organoselenium compounds for potential chemopreventive properties in colon cancer by colonic cell proliferation. Anti Cancer Res., 16:1123-1128. 115. Liu, T., Mokuolo, A.O., Reddy, B.S., Rao, C.V., and Holt, P.R. (1996). Regional chemoprevention of carcinogen-induced tumors in rat colon. Gastroenterology, 109:1167-1172. Rao/CV 16

116. Rao, C.V., Rivenson, A., Kelloff, G.J., and Reddy, B.S. (1995) Chemoprevention of azoxymethane-induced colon cancer by ascorbylpalmitate, carbenoxolone, demethylfumarate and p-methoxyphenol in male F344 rats. Anticancer Res., 15:1199-1204. 117. Singh, J., Rao, C.V., and Reddy, B.S. (1995) Molecular markers in chemoprevention of colon cancer: inhibition of expression of ras-p21 and p53 by sulindac during azoxymethane-induced colon carcinogenesis. Annals NY Acad. Sci. 768: 205-209. 118. Rao, C.V., Rivenson, A., Simi, B., Zang, E., Hamid, R., and Reddy, B.S. (1995) Enhancement of experimental colon carcinogenesis by dietary 6-phenylhexyl isothiocyanate. Cancer Res., 55:4311-4318. 119. El-Bayoumy, K., Upadhyaya, P., Chae, Y-H., Sohn, O.-S., Rao, C.V., Fiala, E., and Reddy, B.S. (1995) Chemoprevention of cancer by organoselenium compounds. J. Cellular Biochem. 22:92- 100. 120. Rao, C.V., Rivenson, A., Simi, B., and Reddy, B.S. (1995) Chemoprevention of colon cancer by dietary curcumin. Annals NY Acad. Sci., 768: 201-204. 121. Singh, J.S., Rao, C.V. and Reddy, B.S. Effect of chemopreventive agents on post-translational plasma-membrane association of ras-p21 during chemoprevention of azoxymethane-induced colon carcinogenesis, Int. J. Oncol. 6: 301-306, 1995. 122. Bartram, H-P, Gostner, A., Reddy, B.S., Rao, C.V., Scheppach, W., Dusel, G., Richter, A., Richter, F., and Kasper, H. (1995). Missing anti-proliferate effect of fish oil on rectal epithelium in healthy volunteers consuming a high-fat diet: potential role of the -3:-6 fatty acid ratio. European J. Cancer Prev., 4:231-237. 123. Rao, C.V., Desai, D., Rivenson, A., Simi, B., Amin, S., and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by phenylethyll-3-methylcaffeate. Cancer Res., 55:2310-2315. 124. Rao, C.V., Rivenson, A., Simi, B., and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally-occurring plant phenolic compound. Cancer Res., 55:259-266, 1995. 125. Rao, C.V., Rivenson, A., Simi, B., Zang, E., Kelloff, G., Steele, V., and Reddy, B.S. (1995) Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal antiinflammatory agent. Cancer Res., 55:1464-1472. 126. Rao, C.V., Reddy, B.S., Simi, B., and Upadhyaya, P. (1994) Potential chemopreventive properties of organoselenium compounds for potential chemopreventive properties against colon cancer. Int. J. Oncol., 5:509-514, 127. Reddy, B.S., Upadhyaya, P., Simi, B., and Rao, C.V. (1994) Evaluation of organoselenium compounds for potential chemopreventive properties in colon cancer. Anticancer Research, 14:2509-2514, 1994. 128. Singh, J., Rao, C.V., Kulkarni, N., Simi, B., and Reddy, B.S. (1994) Molecular markers as intermediate end-points in chemoprevention of colon cancer: Modulation of ras activation by sulindac and phenylhexylisothiocyanate during colon carcinogenesis. Int. J. Oncology, 5:1009- 1018. Rao/CV 17

129. *Reddy, B.S., and Rao, C.V. (1994) Chemoprevention of colon cancer by organosulfur compounds. In: "Food Phytochemicals for Cancer Prevention I", ACS Symposium Series 546., pp.164-172. 130. Bartram, P.-P., Gostner, A., Scheppach, W., Reddy, B.S., Rao, C.V., Dusel G., Richter, F., Richter, A., and Kasper, H. (1993) Effect of fish oil on rectal cell proliferation, mucosal fatty acids, and

prostaglandin E2 release in healthy subjects. Gastroenterology, 105:1317-1322. 131. Rao, C.V., Simi, B., and Reddy, B.S. (1993) Inhibition by dietary curcumin of azoxymethane- induced ornithine decarboxylase, tyrosine protein kinase, arachidonic acid metabolism and aberrant crypt foci formation in the rat colon. Carcinogenesis, 14:2219-2225. 132. Rao, C.V., Desai, D., Simi, B., Kulkarni, N., Amin, S., and Reddy, B.S. (1993) Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res., 53:4182-4188. 133. Rao, C.V., Rivenson, A., Katiwalla, M., Kelloff, G.J., and Reddy, B.S. (1993) Chemopreventive effect of oltipraz during different stages of experimental colon carcinogenesis induced by azoxymethane in male F344 rats. Cancer Res., 53:2502-2506. 134. Reddy, B.S., Rao, C.V., Rivenson, A., and Kelloff, G.J. (1993) Chemoprevention of colon carcinogenesis by organosulfur compounds. Cancer Res., 53:3493-3498. 135. Reddy, B.S., Rao, C.V., Rivenson, A., and Kelloff, G.J. (1993) Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis, 14:1493-1497. 136. Rao, C.V., and Reddy, B.S. (1993) Modulating effect of amount and types of dietary fat on ornithine decarboxylase, tyrosine protein kinase and prostaglandin's production during colon carcinogenesis in male F344 rats. Carcinogenesis, 14:1327-1333. 137. Rao, C.V., Zang, E., and Reddy, B.S. (1993) Effect of high fat corn oil, olive oil and fish oil on the membrane phospholipid fatty acid composition in male F344 rats. Lipids, 28:441-447. 138. *Rao, C.V. and Reddy, B.S. (1992) Inhibitors of prostaglandin synthesis in cancer chemoprevention. In: Eicosanoids and other bioactive lipids in cancer, inflammation and radiation injury. (S. Nigam, K.V. Horn, L.J. Marnett, and T.L. Walden, Jr.. eds.), Proceedings of the 2nd International Conference, Berlin, FRG, September 17-21, 1991, Kluwer Academic Publishers, Massachusetts, pp. 427-429. 139. Reddy, B.S., and Rao, C.V. (1992)"Wresting Anticancer Secrets from Garlic and Soy Sauce- citation." Science, 257:1349. 140. Rao, C.V., Desai, D., Kaul, B., Amin, S., and Reddy, B.S. (1992) Effect of caffeic acid esters on carcinogen-induced mutagenicity and human colon adenocarcinoma cell growth. Chem.-Biol. Interactions, 84:277-290. 141. *Reddy, B.S and Rao, C.V. (1992) Chemopreventive effects of omega-3 fatty acids. In: Cancer Chemoprevention. (L. Wattenberg, M. Lipkin, C.W. Boone, and G.J. Kelloff, eds.), "Workshop on Cancer Chemoprevention", La Jolla, CA, February 2-5, 1991, CRC Press, Boca Raton, pp. 489-501. 142. Rao, C.V., Tokumo, K., Rigotty, J., Zang, E., Kelloff, G., and Reddy, B.S. (1991) Chemoprevention of colon carcinogenesis by dietary administration of piroxicam Rao/CV 18

difluoromethylornithine, 16-fluoro-5-androsten-17-one and ellagic acid individually and in combination. Cancer Res., 51:4528-4534. 143. Rao, C.V., Tokumo, K., Kelloff, G., and Reddy, B.S. (1991) Inhibition by dietary oltipraz of experimental intestinal carcinogenesis induced by azoxymethane in male F344 rats. Carcinogenesis, 12:1051-1056. 144. Rao, C.V., Nayini, J., and Reddy, B.S. (1991) Effect of oltipraz [5-(2-pyrazinyl)-4-methyl-1,2- dithiol-3-thione] on azoxymethane-induced biochemical changes related to early colon carcinogenesis in male F344 rats. Proc. Soc. Exp. Biol. Med., 197:77-84. 145. Engle, A., Hebert, J.R. Rao, C.V., and Reddy, B.S. (1990) Relationships between food consumption and dietary intake among healthy volunteers and implications for meeting dietary goals. J. of the American Dietetic Assoc. 90:526-533. 146. Reddy, B.S., Engle, A., Katsifis, S., Simi, B., Bartram, H., Rao, C.V., Perrino, P. and Mahan, C. (1990) Biochemical epidemiology of colon cancer: Effect of types of dietary fiber on fecal mutagens, and acid and neutral sterols in healthy subjects. Cancer Res. 49:4629-4635. 147. *Reddy, B.S., Nayini, J. Rao, C.V., and Wynder, E.L. (1990) Ütiopathogenese. In: Das Kolorektale Karzinom und seine Präkanzerosen. (J.R. Izbicki, D.K. Wilker, eds.), Walter de Gruyter Berlin, NY, pp. 11-21, 148. Nayini, J., El-Bayoumy, K., Rao, C.V., Sugie, S., Cohen, L.A. and Reddy, B.S. (1989) Chemoprevention of experimental mammary carcinogenesis by the synthetic organoselenium compounds, benzlylselenocyanate, in rats. Carcinogenesis 10:509-512. 149. Nayini, J., Sugie, S., Rao, C.V., El-Bayoumy, K., Rigotty, J., Sohn, O., and Reddy, B.S. (1991) Effect of benzylselenocyanate on azoxymethane-induced colon carcinogenesis. Nutrition and Cancer, 15:129-139. 150. Sairam, M., Rao, C.V., and Seenayya, G. (1990) Characterization of Clostridium thermocellum SS8, a broad saccharolytic bacteria. World J. Microbial & Biotechnol., 2:87-91. 151. Sairam, M., Rao, C.V., and Seenayya, G. (1990) Selective enrichment of Clostridium sp. and Methanobacterium sp. for utilization of cellulose to methane formation. Biotechnol. Lett. 5: 65-71. 152. Rao, C.V, Sairam, M., and Seenayya, G. (1989) Single step conversion of biomass to ethanol by newly isolated strains of Clostridium thermocellum,. In: Bio-Energy (H.L. Sharma, Ed.), DNES, Delhi, 6:78-86. 153. Radha, S., Rao, C.V., and Seenayya, G. (1989) Isolation and characterization of Desulfovibrio sp. from polluted lake sediment. Indian J. Microbiol., 13: 88-94. 154. *Seenayya, G. and Rao, C.V. (1989) Biomass to bio-energy: A Review. In: Bio-Energy (H.L. Sharma, Ed.), DNES, Delhi, 6:20-39. 155. Sridher. P, Seenayya, G, Rao CV. (1988) Toxicity of sodium dichloro S-triazinetrione to Drosophila melanogaster. Bull Environ Contam Toxicol. 41(1):108-13. 156. Rao, C.V., Sairam, M., and Seenayya, G. (1988) Stimulatory and inhibitory effects of heavy metals on methanogenesis and sulfidogenesis. Indian J. Microbiol., 12: 338-345. Rao/CV 19

157. Rao, C.V., and Seenayya, G. (1988) Isolation and characterization of an acetoclastic, non- hydrogen oxidizing methanogenic archaebacterium. Indian J. Microbiol., 12: 48-57. 158. Rao, C.V., and Seenayya, G. (1988) Methanogenesis and temporal distribution of methane producing bacteria in hyper polluted lake. J. Limnol ., 17:136-147. 159. Rao, C.V., and Seenayya, G. (1987) Methanogenic bacteria: An unique biological group. Science Rep., 24:158-161. 160. Rao, C.V., Sairam, M., and Seenayya, G. (1987) Methods for co-culturing of obligate anaerobic bacteria by using PRAMP-technique. Ind. J. Microbiol., 11: 138-145. 161. Rao, C.V., and Seenayya, G. (1987) PRAMP-technique: An easy method to cultivate obligate anaerobic bacteria. J. Microbiol. Methods., 8: 235-246. 162. Rao, C.V., Rao, L.V., Sairam, and Seenayya, G. (1986) Isolation and characterization of high ethanol producing Saccharomyces from lake sediments. Indian J. Microbiol., 11: 88-93. 163. *Rao, C.V., and Seenayya, G. (1987) Stimulation of sediment methanogenesis by heavy metals, Int. Symp. Proceed. In:New Frontiers in Microbiol Technology, (G.H. Godbole, Ed.) pp.208-215. 164. *Rao, C.V., and Seenayya, G. (1987) Fresh water bacterial flora and their methods of study. Symp Proceed. In: Limnology in India, (Zafer, A.K., Ed.) pp. 178-192. 165. Prahalad, A.K., Rao, C.V., Reddy, V.B., and Seenayya, G. (1986) Limitations in accurate analysis of aquatic methyl mercury levels by electron capture detection methodology. J. Limnol., 15: 235-240. 166. *Rao, C.V., Prahalad, A.K., Sairam, M., and Seenayya, G. (1986) Ground water pollution - a need to study. In: "Water Quality in and around Urban Ecosystem and their Management." pp. 81-86. 167. *Prahalad, A.K., Rao, C.V., and Seenayya, G. (1986) Methyl mercury -a potential health hazards compound in aquatic ecosystem.. In: "Water Quality in and around Urban Ecosystem and their Management."pp.56-62. 168. *Seenayya, G., Sairam, M., and Rao, C.V., (1986) Generation and Utilization of methane from organic waste- (pp 32), DNES Publications, Hyderabad, India. 169. Rao, C.V., and Seenayya, G. (1986) Modification of Hungate’s Technique to isolate anaerobic bacteria from lake sediments. Curr. Sci., 34: 276-282. 170. Seenayya, G., Khan, M.M., and Rao, C.V. (1985) Temporal distribution of blue-green algae in fresh and polluted lakes. Hydrobiol., 66: 1342-1348. 171. *Seenayya, G., Khan, M.M., Reddy, E.D., and Rao, C.V., (1985) "A Study into Chemistry and Biology of Lake Sediments" (pp 52), DOE Publications, New Delhi, India. 172. Rao, C.V., Sridhar, P., Reddy, G. and Polasa, H. (1984) Suppression of adenoviral induced CPE in MK cells by Ocimum sanctum extract. Curr. Science., 33: 206-213. 173. Sridhar, P., Rao, C.V. and Polasa, H. (1984) Induction of interferon-gamma in MK cells by Ocimum sanctum extract. Indian J. Microbiol., 8: 65-71. Rao/CV 20

ABSTRACTS (Partial List from 2003-2010) About 220abstracts, presented at National and International Symposia and Conferences (Some of the Abstracts presented at Annual Meeting of AACR for years 1992, 1994, 1995, 1999, 2003, 2005 and 2006, 2010 selected for National Press Release).

1. Rao, C.V., Suresh Guruswamy, Jagan Mohan R. Patlolla, Naveena Janakiram and Venkat S. Malisetty. Chemoprevention of colon cancer by PBIT, an iNOS-selective inhibitor, administered alone or in combination with low-doses of celecoxib, a COX-2 selective inhibitor. Cancer Prev Res 2010;3(1 Suppl):A53. AACR 8th International Conference on Frontiers in Cancer Prevention Research—Dec 6-9, 2009; Houston, TX. 2. Naveena B. Janakiram, Altaf Mohammed, Durgadevi Ravillah, Chang In Choi, Yuting Zhang, Dhimant Desai, Shantu Amin and Chinthalapally V. Rao. Chemoprevention of colon carcinogenesis in F344 rats by Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bis-isoselenourea (PBISe) a novel analog of PBIT, an iNOS inhibitor Cancer Prev Res 2010;3(1 Suppl):A35. AACR 8th International Conference on Frontiers in Cancer Prevention Research—Dec 6-9, 2009; Houston, TX 3. Jagan Mohan R. Patlolla, Yuting Zhang, Li Qian, Vernon E. Steele and Chinthalapally V. Rao Chemopreventive properties of omeprazole against azoxymethane-induced colonic aberrant crypt foci formation in rats. Cancer Prev Res 2010;3(1 Suppl):A141. AACR 8th International Conference on Frontiers in Cancer Prevention Research—Dec 6-9, 2009; Houston, TX. 4. Suresh Guruswamy, Doris Benbrook, Yuting Zhang, Li Qian, Altaf Mohammed and Chinthalapally V. Rao. Chemoprevention of familial adenomatous polyposis by a flexible- heteroarotinoid (Flex-Het), SHetA2, in APCMin mice. Cancer Prev Res 2010;3(1 Suppl):A140. AACR 8th International Conference on Frontiers in Cancer Prevention Research—Dec 6-9, 2009; Houston, TX. 5. Altaf Mohammed, Li Qian, Stan Lightfoot, Steele E. Vernon and Chinthalapally V. Rao. Atorvastatin (Lipitor) delays progression of PanINs to pancreatic carcinoma through AKT pathway in a conditional LSL-K-rasG12D transgenic mice. Cancer Prev Res 2010;3(1 Suppl):A145. AACR 8th International Conference on Frontiers in Cancer Prevention Research— Dec 6-9, 2009; Houston, TX. 6. Rao, C.V. Combinational Molecular Targets: Prevention and Treatment of colorectal Cancer. The 2009 China-US Forum on Frontiers of Cancer Research: Focus on Orevention. Oct 18-22, 2009 Changsha, China. 7. Narayanan K. Narayanan, Lori Horton, Sally Lasano, Maarten C. Bosland, Bhagavathi A. Narayanan and Chinthalapally V. Rao. A novel mechanism for the anti-cancer effects of licofelone against testosterone and estradiol-17β-induced prostate carcinogenesis: Selective modulation of the cross-talk between estrogen receptor and NF-κB. LB-422, 101st AACR Annual Meeting, Washington DC, April 2010. 8. Naveena B. Janakiram, Malisetty V. Swamy, Jagan M. Patlolla, Suresh Guruswamy, Chinthalapally V. Rao. A selective iNOS inhibitor N6-iminoethyl-lysine tetrazoleamide (NILT), suppress invasive colonic cancers and improves preventive efficacy of low-dose COX-2 Rao/CV 21

inhibitor, celecoxib in F344 rats. A-954. 101st AACR Annual Meeting, Washington DC, April 2010. 9. Altaf Mohammed, Naveena B. Janakiram, Li Qian1, Venkateshwar Madka, Misty Ely, Stan Lightfoot, Vernon E. Steele, Chinthalapally V. Rao. Gefitinib, an EGFR inhibitor, prevents progression of PanINs to pancreatic carcinoma in a preclinical conditional LSL-K-rasG12D transgenic mice model. A-2927. 101st AACR Annual Meeting, Washington DC, April 2010. 10. May, R., Sureban, S.M, Lightfoot, S.A, Brackett, D.J, Postier, R.G, Whche, J.H, Rao, C.V., Anant, S, and Houchen, C.W. (2010) Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas. AGA 2010, Annual Meeting, Gastrointest. G310. Florida, May 15-19 11. C. V. Rao, Altaf Mohammed, Li Qian, Naveena B. Janakiram, Chang-In Choi, Yuting Zhang, Stan A. Lightfoot, Vernon E. Steele. Delayed progression of pancreatic carcinoma in a conditional K- rasG12D mice by nitric oxide (NO)-releasing aspirin. AACR Annual Meeting, April 18-22, 2009 Denver, CO. Minisymposium: 12. Altaf Mohammed, Li Qian, Naveena B. Janakiram, Chang-In Choi, Yuting Zhang, Vernon E. Steele, C.V. Rao. Chemoprevention of colon and small intestinal tumorigenesis in ApcMin/+ mice by licofelone, a novel dual 5-LOX/COX inhibitor. AACR Annual Meeting, April 18-22, 2009 Denver, CO. Minisymposium: N 13. aveena B. Janakiram, Altaf Mohammed, Li Qian, Chang-In Choi, Vernon E. Steele, C.V. Rao. Bexarotene, a selective RXR agonist, suppresses intestinal polyp formation and hyperlipidemia in Min mice. AACR Annual Meeting, April 18-22, 2009 Denver, CO. Presentation: 14. Madhu Unnikrishnan, Hiroshi Yamada, Janakiram Naveena basa, Suresh Guruswamy, C.V. Rao.Overexpression of Ets2 in colon carcinogenesis is associated with tumor cell survival. AACR Annual Meeting, April 18-22, 2009 Denver, CO. Presentation: 15. Narayanan K. Narayanan, Dominick Nargi, C. V. Rao, B.A. Narayanan. Chemopreventive efficacy and the underlying molecular mechanisms of anti-inflammatory agent licofelone against prostate cancer. AACR Annual Meeting, April 18-22, 2009 Denver, CO. Minisymposium N 16. Narayanan K. Narayanan, Dominick Nargi, Sally Lasano, Maarten C. Bosland, C.V. Rao.In vivo effects of licofelone against prostate cancer: Inhibition of 5-lipoxygenase pathway and suppression of prostaglandin E2 biosynthesis, independent of cyclooxygenase-2. AACR Annual Meeting, April 18-22, 2009 Denver, CO. Late Breaking Presentation: 17. Rao, C.V. Developing novel dual LOX-COX inhibitors for colon cancer prevention. 1st International Symposium on Cancer Prevention and Treatment. December 18-20, 2009, New Delhi, India. 18. Rao, C.V. Prevention and treatment of epithelial cancers by licofelone.3rd International Conference on Diet and Cancer; Oct 3-6, 2008 Austin, MN. 19. Rao, C.V. Chemopreventoin of colon cancer by statins.39th International Symposium of Princess Takamatsu Cancer Research Fund. Metabolic Syndrome: Carcinogenesis and Prevention. November 11-13, Tokyo, Japan. Rao/CV 22

20. Rao C.V. Chemoprevention of colorectal cancer by combinational agents. Hollings Cancer Center Spring Symposium: March 11-12, 2009:Charleston, SC. Cancer Prevention and Cancer Disparities. 21. Jagan Mohan R. Patlolla, Yuting Zhang, Bhargava Citineni, Rabiya Khan, Chang-In Choi, C.V. Rao. Augmentation of curcumin-induced colon cancer chemopreventive properties by piperine, and β-escin in the rat model and human colon cancer cell lines. Proceed. American Association for Cancer Research, 99th Annual Meeting, San Diego, CA. (April 2008) 22. Hiroshi Y. Yamada, C.V. Rao. Brd8 is a chemosensitizing target for spindle poisons in colorectal tumors. Proceed. American Association for Cancer Research, 99th Annual Meeting, San Diego, CA. (April 2008). 23. Vernon E. Steele, C.V. Rao, Yuting Zhang, Jagan Patlolla, Clinton J. Grubbs, Ronald A. Lubet. Comparative chemopreventive efficacy of Naproxen and NO-Naproxen in rodent models of colon and bladder cancer. Proceed. American Association for Cancer Research, 99th Annual Meeting, San Diego, CA. (April 2008) 24. Naveena B. Janakiram, Yuting Zhang, Chang-In Choi, Altaf Mohammed, Vernon E. Steele, C.V. Rao. Chemopreventive effects of Cucumaria frondosa lipid extract in rat colon carcinogenesis and in a human colon cancer cell line. Proceed. American Association for Cancer Research, 99th Annual Meeting, San Diego, CA. (April 2008). 25. Suresh Guruswamy, Vernon E. Steele, Levy Kopelovich, C.V. Rao. Modulation of RhoA associated signaling by lovastatin and celecoxib in human colon cancer cells. Proceed. American Association for Cancer Research, 99th Annual Meeting, San Diego, CA. (April 2008). 26. Sunil A. Patel, Suresh Guruswamy, Chang Choi, Yuting Zhang, Vernon E. Steele, Howard Ozer, C.V. Rao. A dual lox/cox inhibitor, licofelone, suppresses pancreatic cancer xenografts in athymic nude mice. Proceed. American Association for Cancer Research, 99th Annual Meeting, San Diego, CA. (April 2008) 27. C.V. Rao, Malisetty V. Swamy, Chang I. Choi, Naveena B. Janakiram, Jagan M. Patlolla, Vernon E. Steele. Chemoprevention of colon carcinogenesis by licofelone, a novel dual 5-LOX/COX inhibotor, in F344 rats. Proceed. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA. (April 2007). 28. Naveena B. Janakiram, Vernon E. Steele, C.V. Rao. Combined effects of raloxifene (SERM) and bexarotene (Rexinoid) on growth suppression of colon cancer cells. Proceed. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA. (April 2007) 29. Carla Kurkjian, Suresh Guruswamy, Naveena B. Janakiram, Vernon E. Steele, Howard Ozer, C.V. Rao. The effects of licofelone, a dual lipoxygenase and cyclooxygenase inhibitor, with and without rosiglitazone on human MDA-MB-231 breast cancer cells. Proceed. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA. (April 2007) 30. Suresh Guruswamy, Swamy V. Malisetty, Levy Kopelovich, Vernon E. Steele, C.V. Rao. Caveolin-1 as a target for colon cancer inhibition by lovastatin and celecoxib. Proceed. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA. (April 2007) 31. Jagan Mohan R. Patlolla, Arun K. Sharma, Shantu Amin, C.V. Rao. Tumor promoting effects of alkylcyclobutanones, radiolytic agents generated during the irradiation of meat products. Rao/CV 23

Proceed. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA. (April 2007) 32. Malisetty V. Swamy, Howard Ozer, C.V. Rao. Prevention of pancreatic cancer by curcumin in combination with decosahexaenoic acid: Novel strategies in developing effective chemopreventive regimens. Proceed. American Association for Cancer Research, 98th Annual Meeting, Los Angeles, CA. (April 2007) 33. Rao, C.V., Janakiram, N., Malisetty, V.S., Guruswamy, S., Patlolla, J.M.R., Thungathurthi, R., Kopelovich, L., Steele, V. Chemoprevention of Colon Cancer by Raloxifene, a Selective Estrogen Receptor Modulator. Proceed. American Association for Cancer Research, 97th Annual Meeting, Washington DC. (April 2006) mini-symposium 34. Malisetty, V.S., Guruswamy, S., Patlolla, J.M.R., Thungathurthi, R., Bandaru, R.S., Kopelovich, L., Steele, V., Rao, C.V. Chemoprevention of colon cancer by lovastatin and low-doses of celecoxib administered individually and in combination in F344 rats. Proceed. American Association for Cancer Research, 97th Annual Meeting, Washington DC. (April 2006)- mini- symposium 35. Patlolla, J.M.R., Rashid, H., Steele, V., Rao, C.V. Chemopreventive Properties of Probucol, Purpurogallin and Ethoxyquin against Azoxymethane-Induced Colonic Aberrant Crypt Foci Formation in Rats. Proceed. American Association for Cancer Research, 97th Annual Meeting, Washington DC. (April 2006) 36. Guruswamy, S., Malisetty, V.S., Steele, V., Rao, C.V. Chemoprevention of Colon Carcinogenesis by S-Adenosyl-L-methionine in Male F344 rats. Proceed. American Association for Cancer Research, 97th Annual Meeting, Washington DC. (April 2006) 37. Rao, C.V., Malisetty, V.S., Guruswamy, S., Steele, V.E., Kopelovich, L. Chemoprevention of Colon Cancer by CP-31398, a p53 Rescue Agent Administered Individually or in Combination with Low-Doses of Celecoxib. Proceed. American Association for Cancer Research, 97th Annual Meeting, Washington DC. (April 2006) 38. Rao, C.V., Bandaru S. Reddy C-X Wang, Jagan Patlolla, Barbara Simi, Levy Kopelovich, and Basil Rigas. Chemoprevention of colon cancer by nitric oxidize (NO)-releasing NSAIDs: Strategies for developing safer and efficacious agents for colon cancer prevention and treatment. Proceed. American Association Cancer Research, 96th Annual Meeting, Anaheim, CA. 39. Malisetty V. Swamy, Jagan M.R. Patlolla, Jayadev Raju, and C. V. Rao. Chemoprevention of colon cancer by diosgenin, a steroidal saponin constituent of fenugreek. Proceed. American Association Cancer Research, 96th Annual Meeting, Anaheim, CA. 40. Jagan M.R. Patlolla, Malisetty V. Swamy, Jayadev Raju, Barbara Simi and C. V. Rao. Colon cancer chemopreventive properties of beta-escin, a triterpene saponin constituent of Aesculus hippocastanum. Proceed. American Association Cancer Research, 96th Annual Meeting, Anaheim, CA. 41. Bandaru S. Reddy, Barbara Simi, Jagan M.R. Patlolla, Wang, X.Q., and C. V. Rao. Chemoprevention of colon cancer of by celecoxib in combination with omega-3 fatty acid rich diet: strategies to improve the clinical efficacy of selective COX-2 inhibitors. Proceed. American Association Cancer Research, 96th Annual Meeting, Anaheim, CA. Rao/CV 24

42. C. V. Rao, Yang, Y-M., Malisetty V. Swamy, Liu, T., Fang, Y and Dai, W. Enhanced genomic instability and colon tumorigenesis in BubR1 Apc-min compound mice. (Mini-Symposia) Proceed. American Association Cancer Research, 96th Annual Meeting, Anaheim, CA. 43. Bandaru S. Reddy, Levy Kopelovich, Vernon Steele and C. V. Rao. Chemoprevention of colon cancer of by combination of low-dose celecoxib or aspirin with lipitor. (Late breaking, National Press Release, Min Symposia) Proceed. American Association Cancer Research, 96th Annual Meeting, Anaheim, CA. 44. Das, A, Sinha, R., Narayanan, B., Dasai, D., Amin, S, Fiala, E, Rao, C.V. and El-Bayoumy, K. Molecular targets for chemopreventive agent p-XSE in human non small cell lung cancer cells. Proceed. American Association Cancer Research, 96th Annual Meeting, Anaheim, CA. 45. Malisetty V. Swamy, Jayadev Raju, Jagan M.R. Patlolla, Reddy, B.S. and C. V. Rao Chemoprevention of familial adenomatous polyposis (FAP) by lipitor and celebrex administered individually and in combination to male APCmin-mice. Proceed. American Association of Cancer Research 95th Annual Meeting, 2004, Orlando, FL. (Selected for AACR- Travel Award for Dr. Malisetty). 46. Chinthalapally V. Rao, Malisetty V. Swamy, Jayadev Raju, Joel Reinhardt, and Levy Kopelovich The p53 rescue agent CP-313198 inhibits intestinal adenomas in APCmin mice and aberrant crypt foci in the colon of carcinogen-treated F344 rats. Proceed. American Association of Cancer Research 95th Annual Meeting, 2004, Orlando, FL. 47. Jagan MR Patlolla, Jayadev Raju, Malisetty V. Swamy, Christopher Herzog, Dimant Desai, Shantu Amin and Chinthalapally V. Rao Enhancement of NNK-induced lung tumorigenesis by western style diet. Proceed. American Association of Cancer Research 95th Annual Meeting, 2004, Orlando, FL. 48. Jayadev Raju, Jagan M.R. Patlolla, Malisetty V. Swamy, and Chinthalapally V. Rao. Colon cancer preventive effects of Trigonella foenum graecum (fenugreek) seed and its constituent diosgenin using in vitro and in vivo models. Proceed. American Association of Cancer Research 95th Annual Meeting, 2004, Orlando, FL. 49. Chinthalapally V. Rao, Barbara Simi, Jayadev Raju, Malisetty V. Swamy, Jagan MR Patlolla, Vernon E. Steele, Levy Kopelovich and Bandaru S. Reddy. ER, RXR, PPAR-, HMG-CoA Reductase, and HDAC as Molecular Targets for the Chemoprevention of Colorectal Cancer. Proceed. American Association of Cancer Research 95th Annual Meeting, 2004, Orlando, FL. 50. Jagan MR Patlolla, Malisetty V. Swamy, Jayadev Raju and Chinthalapally V. Rao. Over- expression of caveolin-1 in experimentally induced colon adenocarcinomas and human colon cancer cell lines. Proceed. American Association of Cancer Research 95th Annual Meeting, 2004, Orlando, FL. 51. Malisetty V. Swamy, Indranie Cooma, J.M.R. Patlolla, Barbara Simi, Bandaru S. Reddy and Chinthalapally V. Rao. 2003. Modulation of COX-2 and iNOS activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention. (Selected for National Press Release; Mini Symposia. 94th AACR Annual Meeting July 11-14, Washington DC. 52. Malisetty V. Swamy, Christopher R. Herzog and Chinthalapally V. Rao. 2003. Inhibition of COX- 2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Poster Discussion. 94th AACR Annual Meeting July 11-14, Washington DC. Rao/CV 25

53. J.M.R. Patlolla, Malisetty V. Swamy Cesar Aliga, Barbara Simi, Bandaru S. Reddy and

Chinthalapally V. Rao. 2003. Genetic and epigenetic regulation of secretary phospholipase A2 influences experimental colon carcinogenesis. Poster Discussion. 94th Proceed. AACR Annual Meeting July 11-14, Washington DC.

TEACHING/RESEARCH ADVISEES  2004-Present, Graduate Faculty (GPiBS), Pathology Department, Research Advisor committee Chairman and Member, Graduate Rotations, Graduate Students  2005-Present, Research Director, Medical Oncology, One –Year Research (Third year Fellows)–Basic and Translational Research.  2001-2004, Graduate Student Advisory Committee (Ph.D. Program), Dept. of Pathology, New York Medical College, Valhalla, NY  5/1999-4/2001, Research Professor (Adjunct), Dept. of Microbiology, New York Medical College, Valhalla, NY (Graduate course entitled "Gut microbial flora in colon cancer, and prebiotics and probiotics")  6/1996-4/1999, Research Associate Professor (Adjunct), Dept. of Microbiology and Pathology, New York Medical College, Valhalla, NY (Graduate course entitled: Role of Macro- and Micro- Nutrients in cancer and Disease Prevention)  7/1995-2/1996, Research Associate Professor (Sabbatical), SABA School of Medicine, Saba, The Netherlands. Teaching Courses in Medical Microbiology and Immunology at the Medical School.  1/1984-7/1988, Lecturer for graduate courses (Environmental Microbiology/ Molecular Biology/Immunology), Department of Microbiology, Osmania University, Hyderabad, India.

Partial List of ( Full-time) Candidates (Ph.D/ M.D.) Trained in Research Name Year/Role Current Position Jaya Nayani, Ph.D (1992-1994)/Post-doc Senior Scientist, Abbott Labs Parati Siva Kumar, Ph.D. (1992-1994)/ Post-doc Manager, Ranboxy Inc., Tin Tin Wynn, M.D. (1994-1995) Post-doc Clinician, Private Pract. Thoshiko Kawamori, M.D, Ph.D (1994-1998)/Post-doc Associ. Prof, U. Hawaii Samaha Hannah, M.D., Ph.D. (1995-1997)/Post-doc Assoc. Prof. Central Uni. NC Yoshi Hiroshi, M.D. (1998-2001)/Post-doc Assoc. Prof., Gifu Uni. Jeanne Williams, Ph.D. (1999-2001)/Post-doc Assit. Prof. SUNY, NY Gagan Pandya, Ph.D. (1999-2001)/Post-doc Scientist, Tiger Biotech, MD Jayadev Raju, Ph.D. ((2001-2004)/Post-doc Staff Scientist, USDA, Canada Malisetty V Swamy, Ph.D. (2000-2007) /Lab-Manager V.P of Research, Pharma- Tech, India Jagan M.R. Patlolla, Ph.D. (2001-2008) /Res. Assoc Assit. Prof. Res., OUHSC/OUCI Naveena Basa, Ph.D. (2004-2010) /Res. Asoci Assit. Prof. Res., OUHSC/OUCI Suresh Guruswamy, Ph.D. (2005-2010)/Res. Assoc Faculty, U. of Tulsa, OK Rao/CV 26

Carla Kurkjian, M.D. (2006-2007)/ Onc-Fellow Assit. Prof. OUCI, OUHSC Yuting Zhang, M.D (2006-Pres)/ Res. Assoc OUHSC/OUCI Sunil Patel, M.D. (2007-Pres)/ Onc-Fellow Private Practive Qiun Li, M.D. (2007-Pres)/Res. Tech OUHSC/Hem-Onc Hiroshi Yamada, Ph.D (2007-Pres)/Res. Ass. Prof. OUHSC/Hem-Onc Altaf Mohammed, Ph.D (2008-Pres)/Res. Associ. OUHSC/Hem-Onc Ely Misty, BS, ABAT (2009-Pres) Tech. OUHSC/Hem Onc Rabya Khan, M.D. (2007-Pres)/ Res. Intern OUHSC/Hem/Onc

Partial List of Candidates (M.S./B.S) Trained in Research Barbara Simi, MS (1989-2004)/Senior Tech Rutgers, University Nalani Kulkarni, MS (1990-1993)/Res. Tech Scientist, Pfizer Phar. Bipen Kaul, BS ((1989-1990)/Res. Assit. Oncologist, Privt. Pract. Manisha Katiwalla, MS (1992-1994)/Res. Tech. Clinical Practice Neha Patil, BS (1994-1995)/Res. Assit. Clinician, Privt. Pract. Kathryn Garr, MS (1992-1995)/ Res. Tech Taconic Labs, NY Rashid Hamid, MS (1992-1997)/Res. Tech Purdue Pharma Cesar Aliga, MS (1996-2004)/Animal Biol. Psychogenics Jeffery Rigotty, BS (1996-2004)/Animal Biol. NY Medical College Indrani Cooma, MS (1998-2003)/Res. Tech. Research Admin, U. Conn, CT Lee Ann Marcus, MS (1999-2004)/Animal Biol. Perdue Pharma Chang-In-Choi, M.S. (2005-2009.) Anima Boil. Manager-OUHSC Ashley Duff, B.S., (2009-Pres.)/ Res. Tech OUHSC Meghna Mehta, M.S. (2010-Pres)/Res. Assoc. OUHSC Laura Barton, B.S. (2010-Pres.)/Res. Tech OUHSC Altaf Mohammed, M.S. (2005-2008) Graduate (Ph.D) OUHSC *Madhu Unnikrishnan (2007-pres.) Graduate (Ph.D) OUHSC *Durga Devi (2009-Pres.) Graduate (Ph.D) OUHSC

Participated actively in advising medical GI fellows (~10), and Ph.D (6), and MS (6) graduate students. Advised (Primary and Associate) Graduates for their Dissertations leading Ph.D and MS. Assessed number of Ph.D and MS level Thesis/Dissertations. * Current Ph.D Graduate Students

SELECTED PROFESSIONAL ACTIVITIES  Member, NIH/NCI, Chemoprevention/Dietary Prevention Study Section (CDP), Feb 2004-June, 2009).  Member, Site Visit Team-Cancer Center Program-Kimmel Cancer Center, Thomas Jefferson University, October 16-18, 2007. Rao/CV 27

 Member, NIH/NCI, Program (P01) Projects Clusters (Basic and Translational) Review Groups: Discovery and Development, Cancer Therapeutics; Prevention and Molecular Oncology, 2004- present  Adhoc Member, NIH/NCI, Cancer Biomarkers Study Section (CBSS), 2003-Present.  Member, NIEHS/NCI, Special Emphasis Panel; Prevention & Epidemiology, April 2000 to Nov 2003.  Member, NIH/NCI, Site Visit Team -Program Project on “Natural Inhibitors of Carcinogenesis”, Purdue University, Feb 16-18, 2004.  Member, NIH/NCI, Site Visit Team -Program Project on “Inhibition of Carcinogenesis by Tea and Tea Constituents”, Rutgers University, May 17-19, 2000; Member, Tele Review Panel for same Program Project, January 11, 2001.  Member, NIH/NCI, Site Visit Team -Program Project on “Molecular & Clinical Approaches to Colon Cancer Precursors”, Huntsman Cancer Institute, The University of Utah, Novermber18-20, 2002; Member, Tele Review Panel for same Program Project, March 25, 2003.  Member, NCI Special Emphasis Panel, ZCA1 SRRB-Q (J1), U54: Cooperative Grants for Nutritional Modulation of Genetic Pathways Leading to Cancer, November 6-8, 2002.  Adhoc Member, NIH/NCI, Subcommittee E – Cancer Epidemiology Prevention & Control, Scientific Review Group, October 2001; April 2002.  Member, NIEHS Special Emphasis Panel, ZES1 BKW-C (R03), NIH, July 15-18, 2001.  Ad-hoc Member, NIH/NCI, Metabolic Pathology Study Section, 2000- 2002.  Member (Mail Reviewer/Teleconference), NIH/NCI, Cancer Molecular Pathology, Radiation Oncology & Chemical Pathology (SEP) Study Sections 2001-2003.  External (mail) Reviewer for Dutch Cancer Society (1999 –present); Health Research Board, Ireland (2000 –present); Linus Pauling Institute (1999-2002).  External Scientific Advisor, Cancer Prevention Group, National Cancer Center, Tokyo, Japan (January 1999 – present).  Member, American Association for Cancer Research (AACR) Program Committee (2007-Present)  Organizing Committee Co-Chairman, International Symposium on Cancer Prevention and Targeted Therapies, New Delhi, India, Dec 18-21, 2008.  Organizing Committee Co-Chairman, “International Symposium on Cancer Chemoprevention” Crete, Greece, Oct 12-14, 2007.  Member, Organizing Committee, “Natural Products and Translational Research” Lonavala, India, 2007.  Member, Organizing Committee, Keystone Symposia, “Molecular Medicine of Colorectal Cancer”, 2002, Taos, New Mexico.  Member, Organizing Committee, International Symposium, Dietary Factors and Cancer Prevention”, 2004, Rochester, MN.  NCI, Task Force Cancer Chemopreventive Drug Development, (May 2002). Rao/CV 28

 NCI, Task Force, Nutritional Modulation of Genetic Pathways Leading to Cancer, (February 2002)  AMCAM, Task Force, CAM Use in Cancer Patients, Orlando, FL (May 2005)  Consultant, International Center for Food Safety, Washington, D.C.  Consultant, Real honey Bee Products, Inc. Philadelphia, PA (1994-1998)

Editorial Services  Associate Editor, Nutrition and Cancer  Associate Editor, Molecular Carcinogenesis  Associate Editor, International J. Oncology  Senior Editor, Journal of Carcinogenesis  Associate Editor, International Journal of Cancer Prevention  Reviewer, for more than 30 different Cancer Journals

Invited Lectures (Partial List, Since 1999) 2008-2009  Combinational molecular targets for prevention and treatment of colorectal cancer: Promise and Progress. August 14, 2009, University of Pittsburgh Cancer Institute.  Developing novel dual LOX-COX inhibitors for colon cancer prevention. 1st International Symposium on Cancer Prevention and Treatment. December 18-20, 2009, New Delhi, India.  Prevention and treatment of epithelial cancers by licofelone. 3rd International Conference on Diet and Cancer; Oct 3-6, 2008 Austin, MN.  Chemopreventoin of colon cancer by statins. 39th International Symposium of Princess Takamatsu Cancer Research Fund. Metabolic Syndrome: Carcinogenesis and Prevention. November 11-13, Tokyo, Japan.  Chemoprevention of colorectal cancer by combinational agents. Hollings Cancer Center Spring Symposium: March 11-12, 2009:Charleston, SC. Cancer Prevention and Cancer Disparities.

2007  “Natural Products and Translational Research”, Mumbai, Lonavala, India, December  “Mutagenesis, Carcinogenesis and Cancer Prevention, Jeuju Islands, S. Korea, Nov/Dec  “Bioactive Food Components and Cancer Chemoprevention”, Crete, Greece, October  Rutgers, The State University of New Jersey, June  OUHSC, Stewart Wolf Residents’ Research Forum, May  The University of Minnesota, The Hormel Institute, May Rao/CV 29

 The University of Colorado Health Sciences Center, Denver, CO, February  BioAsia, The Global Bio Business Forum, Hyderabad, India, January 2006  The University of Louisville, KY, December  MD Anderson Cancer Center, The University of Texas, Houston, TX, October  Indo-American Cancer Institute and Research Center, Hyderabad, July  Center for Cellular and Molecular Biology (CCMB), Hyderabad, India, July  Indian Institute for Chemical Technology, Hyderabad, India, July  Department of Biochemistry, Osmania University, Hyderabad, India, July  National Defense Research Labs, New Delhi, India, July  National Institute of Nutrition (NIN), Hyderabad, India, June  Department of Animal Sciences, University of Hyderabad, India, June  Department of Microbiology, Osmania University, Hyderabad, India, June  Keystone Symposia, “Molecular Targets for Cancer Prevention” Lake Taos, CA, March 2005  Department of Pathology and Breast Cancer Institute, OUHSC, OK, November  Scientific Symposia, American Association for Clinical Oncology, Orlando, FL, May  Department of Medicine, State University of New York at Stony Brook, NY, March  Department of Pathology, Medical University of South Carolina, Charleston, SC, January. 2004  Frontiers in Cancer Prevention Research, Seattle, Washington. October  International Symposium “Dietary Factors and Cancer Prevention”, Rochester, MN, September.

 Department of Medicine, Cornell (Medical Center) University, New York, NY, April.  Penn State Cancer Institute, Penn State University Medical Center, Hershey, PA, March.  Department of Pathology, Upstate SUNY, Syracuse, NY, March.  Department of Surgical Oncology, Chemoprevention Program, Washington University, January 2003  National Symposia “Anti-oxidants and Chronic Disease Prevention” Tarrytown, NY, December.  University of Connecticut Cancer Center, Farmington, CT, November.  8th World Congress on Advances in Oncology and 7th International Symposium on Molecular Medicine. Crate, Greece, October. (Chair). Rao/CV 30

 Department of Human Nutrition and Health Effects, State University of New York, Buffalo, NY August.  Department of Environmental Sciences, NYU School of Medicine, Tuxedo, NY, May.  NCAM Task force/Symposia “Role of NCI Cancer Centers in Alternative and Complementary Medical Research” Baltimore, April.

2002  Center Cellular and Molecular Biology, Hyderabad, India, December  Frontiers in Cancer Prevention Research, Boston, MA. October 14-18.  M.D. Anderson Cancer Center, GI Cancer Group, Houston, TX, September.  Falk Symposium on “Exogenous Factors in Colonic Carcinogenesis”, Wurzburg, Germany, May 2-3.  College of Pharmacy, Rutgers, the State University of New Jersey, March.  Molecular Medicine of Colorectal Cancer, Keystone Symposia, Taos, New Mexico, February. 2001  Second Annual Perspectives in Colorectal Cancer, Miami, FL, September 28-29.  Department of Gastroenterology, University of Connecticut Health Center, Farmington, CT, August.  Division of Cancer Prevention, AMC Cancer Center, Colorado, July.  Department of Pathology, Gifu University, Gifu, Japan, February.  COX-2 Inhibitors in Chronic Disease Prevention, Pfizer Italia, New York, NY.  First Department of Pathology, Nagoya University, Nagoya City, Japan, February.  Division of Cancer Etiology and Prevention, National Cancer Center, Tokyo, Japan, January.  Department of Environmental Health Sciences, Tokyo University, Japan, January. 2000  International Biotechnology Congress, Millennium Symposia, Hyderabad, India, August 5-8.  Carcinogenesis and Cancer Prevention: Colon Cancer, University of California, Irvine, CA, July 7-9.  Fourth Congress of the International Society for the Study of Fatty Acids and Lipids, Tsukuba, Japan, June 4-9. (Chair)  Division of Population Science, Fox Chase Cancer Center, PA, March 28. 1999  Strang Cancer Prevention Center, New York, NY, December 12.  Fourth World Congress on Advances in Oncology and Third International Symposium on Molecular Medicine. Athens, Greece, October 19-21. (Chair) Rao/CV 31

 NCFM and Probiotics Symposium, Madison, WI, September 9-10.  International Conference “Dietary Prevention of Cancer”, Tampere, Finland, May 28 –June 2.  Nutritional and Health Benefits of Inulin and Oligofructose Conference, Bethesda, MD, May 18-19.

ADMINISTRATION  Chief, Division Nutritional of Carcinogenesis (2001-9/2004). Provide leadership for Division, Containing 28 Employees (8 Faculty, Investigators, 18 Post-docs, 8, Research Techs and 2 administrative Assistants). As a Chief of the Division, managed budgets ~$6.2 million/year.  Associate Chief, Division of Nutritional Carcinogenesis (1999-2001), Coordinate with Divisional Chief and Administration to successfully implement the operations and objectives of Division of Nutritional Carcinogenesis.  Director, Center for Chemoprevention and Cancer Drug Development (August 2009-Pres.) Provide the leadership in co-coordinating and developing Cancer chemoprevention Research and cancer drug developmental activities at the OU Health Sciences Campus.  Chairman, OU Cancer Institute Scientific Advisory Committee (June 2006-Julu 2009). Provide the leadership in developing Cancer Center Research Programs towards the achieving the Center for Excellence and the NCI Designation.  Member, Executive Committee, University of Oklahoma Cancer Institute (Oct. 2004-present). Co-Director, Cancer Prevention and Control Program at the OUCC; Director, Chemoprevention Program at the OUCC. Provide leadership in develop planning in establishing Cancer Chemoprevention Program and strengthen the OU Cancer Insitute for NCI designation (P30- Application)  Member, Rodent Barrier Facility, Operational Planning Committee Member, (Feb. 2005 – present). Develop Animal Core Facility that meet challenges of Cancer Center Investigators in Coordination with OUHSC Animal Facility Chairman and members.  Chairman, Institutional Animal Care & Use Committee (IACUC-Institute for Cancer Prevention, IFCP)-(4/04-12/04).  Co-Chairman, Operations Committee, Institute for Cancer Prevention, IFCP, American health Foundation Cancer Center, (2002-Sep 2004). Develop strategic planning and monitor progress of organization. This Committee is responsible making budgetary decisions; evaluating and managing administrative decisions to overall development of Organization.  Member, Seminar Committee, American Health Foundation Cancer Center (2000- Sep 2004). (Chair, 2002-2003)  Member, Scientific Advisory Committee, AmericanHealth Foundation-Cancer Center, Institute for Cancer Prevention (2001- Sep 2004). Cancer Center Scientific Planning Committee, to oversee Cancer Center Research programs, including recruitments, and decision making on tenure & promotions. Memberships  Member, American Association for Cancer Research.  Member, American Gastroenterological Association Rao/CV 32

 Member, American Association for Advancement of Science  Member, American Chemical Society  Member, American Society for Microbiology (1989-1996)

Awards/Fellowships  OU Regents Award for Superior Research and Creative Activity (2009)- Board of Regents University of Oklahoma.  Outstanding Achievement Award in Cancer Research (2007), The Society of Asian American Scientists in Cancer Research (SAASCR), at the AACR meeting, LA, CA.  Dr. and Mrs. W.W. Kerley and Mr. and Mrs. Cash Cade Endowed Chair in Clinical Cancer Research (2004-Pres.), OUHHC.  Invited Scientist Award, (January-February 2001), From Japanese Ministry of Health (Foundation for Promotion of Cancer Research Award, National Cancer Center Tokyo, Japan,).  Council of Scientific & Industrial Research, 1988, Young Scientist Award, CSIR, New Delhi, for development of novel technologies for isolation of microbes from extreme environment (PRUMP-Unit).  Research Associate Fellowship, (Dec 1987) Department of Non-Conventional Energy, New Delhi, for developing methanogenic bacteria for bio-energy production.  Senior Research Fellowship, (1986-87), Awarded by Council of Scientific & Industrial Research, New Delhi.  Junior Research Fellowship, (1984-85), Awarded by Council of Scientific & Industrial Research, New Delhi.

Summary of Dr. Rao’s Education and Professional Experience

Dr. Chinthalapally V. Rao, he is Kerley-Cade Endowed Chair in Cancer Research, Distinguished Professor of Medicine, in Medical Oncology Section, and Director of the Center for Chemoprevention and Cancer Drug Development Program at the University of Oklahoma Cancer Institute, OU Health Sciences Center (OUHSC) in Oklahoma City. Dr. Rao holds the appointments at the Graduate School (Professor) and Department of Pathology (adjunct Professor). Also, he is the Leader of the Aerodigestive tract Cancers/Chemoprevention Program (2004 to 2009) and Chairman of the Scientific Advisory Committee (2006-2009) at the OU Cancer Institute.

Dr. Dr. Rao earned B.S. degree in Biology and Chemistry; M.S. (1983) and Ph.D. (1987) degrees in Microbiology from the Osmania University, Hyderabad, India. Dr. Rao joined University of Oklahoma Health Sciences Center 2004. Previously he held the Chief, Division of Nutritional Carcinogenesis and Leader of Chemoprevention Program at the American Health Foundation (AHF)-Cancer Center, an NCI- designated Cancer Center, Valhalla, New York. Dr. Rao joined AHF-Cancer Center in 1988 as a Senior Research Fellow and appointed in 1992 as a Member of American Health Foundation Cancer Center (AHF-CC) and Section Head of the Division of Nutritional Carcinogenesis and by 2001, he came up through the ranks to become Division Chief, and Cancer Center Program Leader of Chemoprevention and Nutritional Carcinogenesis. Rao/CV 33

Summary of Dr. Rao’s Major Research Accomplishments

Dr. Rao, a leading authority on colon cancer prevention by targeted chemopreventive agents and nutritional manipulation. His research utilized transgenic and chemically-induced rodents as model systems for better understanding the role of genetic factors and nutritional factors in colorectal cancer risk, more importantly in development of chemopreventive agents for human colorectal cancer prevention.

Dr. Rao research focus on prevention of colon cancer by utilizing nutritional and chemopreventive agents. This approach to colon cancer control is of growing importance, as therapeutic modalities alone have not been fully effective in counteracting either the high incidence or low survival rates. Since the development of promising nutritional and chemoprevention strategies for colon cancer prevention and control requires a strong multidisciplinary approach, over the years Dr. Rao assembled diverse members with varied disciplines to be part of his integrated collaborative research program with the ultimate goal of colon cancer prevention. Dr. Rao’s research focused on the development of novel chemopreventive agents both naturally-occurring and their synthetic analogues and most importantly, establishing molecular targeted chemopreventive drug development and combinational chemopreventive approaches for the prevention of colon cancer

CHEMOPREVENTION OF COLON CANCER:

The long term scientific goals of Dr. Rao’s laboratory have been to identify epidemiology- and mechanism-based strategies; and molecular targeted approaches for colon cancer prevention by chemopreventive agents. Apply this knowledge obtained from preclinical efficacy and mechanistic studies to the population at large with eventual aim of developing preventive strategies for individuals at high risk for colon cancer development as means of secondary prevention. Included in these goals are identification of specific molecular targets and pathways that can be modified by new chemopreventive agents. Dr. Rao also stresses the importance of a concept that the chemopreventive agents administered in combination have the potential to be more selective for colon cancer prevention with increased efficacy without unwanted side effects. Dr. Rao is noted for his pioneering work in the chemoprevention of colon cancer in preclinical models by number of naturally-occurring agents such as curcumin, caffeic acid esters, organosulfur compounds (dithole- thione/Oltipraz/anithole-trithione, diallyl disulfide, aryl-isothiocyates, sulforaphane, perilyll alcohol, triterpenoids, diosgenin, frondanol, farnesol/lanosterol/ squalene; organoselenium, and molecular targeted synthetic agents for ODC, COX-1 and COX-2 selective inhibitors, iNOS-selective inhibitors, HMG-CoA Reductase inhibitors, dual COX-LOX inhibitors and P53 modulating agents..

Following are Dr. Rao’s preclinical studies that lead to Phase I and Phase II clinical trials and/or actively considered for translation research.

Molecular targeted chemopreventive agents and other promising chemopreventives for colorectal cancer prevention

 Cyclooxygense (COX) Inhibitors: Preclinical studies conducted in by Dr. Rao in collaboration with Dr. Reddy and the NCI provided convincing evidence that administration of NSAIDs including aspirin, ibuprofen, piroxicam and sulindac during initiation and postinitiation stages suppressed colon tumorigenesis. Of particular importance is that piroxicam, and sulindac administered during promotion/progression stage of carcinogenesis (at which time premalignant lesions Rao/CV 34

(adenoma) are known to have developed) dramatically suppressed colon tumors suggesting that these agents can be used in secondary prevention among patients with colonic polyps (Cancer Res., 51:4528-4534, 1991; Carcinogenesis, 14:1493-1497, 1993; Cancer Res, 55:1464-1472, 1995; Cancer Res., 59:3387-3391, 1999). In conclusion, preclinical efficacy studies conducted in Dr. Rao’s laboratory and elsewhere have provided a strong case that use of NSAIDs is effective in reducing the risk of colon cancer in humans. In fact results of these preclinical studies served, in part, as a basis for several human clinical trials.

 Cyclooxygenase-2 (COX-2) Inhibitor. Prolonged administration of NSAIDs can cause unwanted side effects, such as s gastrointestinal bleeding, ulceration, and renal toxicity, which are manifested mainly by the blocking of COX-1 activity. Because NSAIDs can affect the activity of both COX-1 and COX-2, which accounts for their chemopreventive as well as their adverse side effects. Pioneering studies conducted by Dr. Rao in collaboration with Dr. Reddy provided preclinical evidence that celecoxib, a specific COX-2 inhibitor with significant anti-inflammatory profoundly inhibited development of colonic tumors in rats. Also, continuous administration of celecoxib throughout the initiation and postinitiation phases as well as promotion/progression stage significantly suppressed the colonic adenocarcinomas and the degree of inhibition of colon carcinogenesis by celecoxib exceeded that seen with any NSAIDs and many chemopreventive agents (AACR, 93: 267, 1994; Cancer Res., 56: 4566-4569, 2006; Cancer Res., 58:409-412; Cancer Res., 60: 293-297, 2000). Based on these preclinical trials, human phase II chemoprevention trials of select COX-2 inhibitors are completed with in patients with colonic polyps. Also, clinical studies conducted elsewhere in a number of patients have demonstrated a reduction of colonic polyp number and size in FAP as well as sporadic patients administered celecoxib. This led the FDA to approve celecoxib for reduction of polyps in FAP patients as an adjunct to endoscopic surveillance and surgery. However, later clinical trials suggested that long-term high dose administration lead to increased cardiovascular side-effects.

 NO-NSAIDs and Phospho-NSAIDs: To avoid unwanted side effects of NSAIDs, Dr. Rao in collaboration with Dr. Rigas provided evidence that nitric-oxide releasing-aspirin and – indomethacin and phospho-ibuprofen suppress colon adenocarcinomas (Mol. Cancer Ther., 5: 1530-1538, 2006; Cancer Prev. Res., 2:951-956, 2009). These studies become the basis for ongoing Phase II clinical trails with NO-NSAIDs for colonic ACF prevention.

 Inhibitors of Molecular Targets (ODC, iNOS, HMG-CoA reductase; p53 and EGFR) Associated with Tumor Growth. Systematic evaluation of classes of agents acting at molecular targets is an important strategy of Dr. Rao’s laboratory for identifying and characterizing new potential Ornithine decarboxylase (ODC), inducible nitric oxide synthase (iNOS) inhibitors and HMG Co-A reductase inhibitor and Ras farnesylation inhibitor for their potential chemopreventive properties against colon cancer in preclinical models. Studies conducted thus far in Dr. Rao’s laboratory provided experimental evidence that these agents suppress colon carcinogenesis (Cancer Res, 51:4528-4534, 1991; Gastroentrology, 117:838-847, 1999; Carcinogenesis, 20:641- 646, 2000; Int. J. Oncol., 20:753-759, 2002; Cancer Res., 63:5239-5242, 2003; Mutat.. Res, 555:107-119, 2004;Cancer Res., 66:4542-4546, 2006; Cancer Res., 68:7670-7675, 2008; Cancer Res., 69:8175-8182, 2009)provided basis for on going clinical trials with statin alone or combined with other agents. The database obtained from these preclinical studies could help to translate laboratory finding to the human setting by initiating human clinical trials.

 Organoselenium agents: Dr. Rao’s other research area is development less toxic and efficient organoselenium compounds for colon cancer prevention. In collaboration with the American Rao/CV 35

Health Foundation scientists Dr. Rao’s established several synthetic Organoselenium compounds including 1,4-phenylenebis(methylene)selenocyanate and its glutathione conjugate hold a great promise as chemopreventive agents since they have been found to be far less toxic, yet four-fold effective than inorganic selenium or seleno-methionine in inhibiting colon carcinogenesis (Int. J. Oncol., 5:509-514, 1994; Anti Cancer Res., 16:1123-1128, 2006; JNCI, 87:506-512, 1997; Int. J. Oncol., 13:29-34, 1998; Carcinogenesis, 21: 617-621, 2000; Cancer Res., 61:3647-3652, 2001). It is noteworthy that 1,4-phenylenebis(methylene)selenocyanate is undergoing toxicological evaluation and has been approved for the further human clinical trials. Also, Dr. Rao’s studies provided evidence that selenomethionine applied Nations largest clinical (SELECT) trial failed to provide any tumor inhibitory effects in colon cancer models (Int. J. Mol. Med., 5:327-330, 2000), in fact, that is true for the SELECT trial..

 Combinational Strategies for colon cancer prevention. This approach is extremely important when a promising chemopreventive agent demonstrates significant efficacy but may produce toxic effects at higher doses. An example of combinations of agents producing positive results in preclinical efficacy models has been a study in which the NDAID piroxicam, and difluoromethylornithine (DFMO), were evaluated for their chemopreventive efficacy by Dr. Rao’s research. An important finding of the study was that lowest dose levels of piroxicam and DFMO when administered together were more effective in inhibiting the incidence and multiplicity of colon adenocarcinomas than administration of individual compounds even at higher levels((Cancer Res, 51:4528-4534, 1991). Such combinational strategies in that targeting different tumor promoting pathways have been tested by Dr. Rao and proven to be very effective in inhibiting colon carcinogenesis (Carcinogenesis, 20:1645-1648, 1999; Gastroentrology, 117:838-847, 1999; Cancer Res, 62:165-170, 2002; Int. J. Oncol., 20:753-759, 2002;Cancer Res, 66:4542-4546, 2006; Cancer Res., 66: 7370-7377, 2006; Gene Reg and Sys Biol., 2: 1-14, 2008; Int. J. Oncol., 35: 1037-1047, 2009; Cancer Res., 69:8175-8182, 2009; ) using NSAIDs and various chemopreventive agents. Notably, Dr. Rao’s studies provided basis for NSAID (sulindac) combined with ODC inhibitors (DFMO) Phase II clinical trial for FAP patient colonic polyp inhibition. This recently concluded clinical shown that >90% polyp prevention without any side effects, thus suggesting unequal evidence for combinations chemopreventive drug development.

 Combinational strategies using effective chemopreventive agent with dietary manipulation: Dr. Rao’s approach to colon cancer prevention in high risk individual should use of low-dose effective chemopreventive agent with low-risk or colon cancer preventive diet. He is first to provide the evidence that use of low-dose COX-2 inhibitor or non-toxic natural chemopreventive such as curcumin combined with fish oil rich diet may provide better efficacy and more practical for chemoprevention of various cancers (Mol. Cancer Therap., 4:215-221; 2004; Cancer Res, 65:8022-8028, 2005;Nutri. Cancer, 60:81-89, 2008). These data strongly support the view that the use of combinations of chemopreventive agents that have diverse actions should have beneficial applications in human cancer chemoprevention trials.

Naturally-Occurring Agents: Colon Cancer Prevention

 Curcumin: A principle component of turmeric consumed in curry powder as dietary supplement. Dr. Rao’s laboratory is the first to establish colon cancer preventive role of pure curcumin against the azoxymethane-induced rat colon adenocarcinoma model. Additional studies in Rao’s laboratory provided possible mechanistic insights of curcumin in colon cancer inhibition and potential of colon adenoma suppressing effects in rats (Carcinogenesis, 14:2219-2225, 1993; Rao/CV 36

Cancer Res, 55: 259-266; 1995; Annal NY Acad Sci, 768: 201-203, 1995; Cancer Res., 59: 597-601, 1999). Dr. Rao’s research has been instrumental for number human clinical trials for colon cancer prevention through-out world and currently several ongoing clinical trials with curcumin for various other organ-sites cancer prevention or treatment and/or as a chemotherapeutic adjuvant.

 Caffeic acid esters: A principle components of honey bee “propolis”. Caffeic acid phenethyl ester (CAPE) and its analogs are anti-carcinogenic and anti-tumorigenic in the in vitro assay carried by Dr. Rao (Chem.-Biol. Interactions., 84: 277-290, 1992). Based on these initial observations, Dr. Rao’s laboratory shown the potential chemopreventive properties of caffeic acid esters in animal models of colon cancer and possible mode of action of this agents in the suppression of colonic tumors (Cancer Res, 53:4182-4188, 1993; Cancer Res, 55:2310-2315, 1995). This research work on the caffeic acid esters derived from propolis was highlighted in NIH/NACAM annual reports (2006) as one of the promising molecules for cancer prevention. Currently, there are three ongoing Phase II clinical trials with CAPE to test cancer inhibitory effects.

 Oltipraz/organosulfur compounds: Oltipraz and its synthetic analog anethole-trithione as potent modulators of Phase II enzymes through the activation of Nrf-2. Dr. Rao and his collaborators are first to show that Oltipraz and anethole-trithione inhibitors of colon carcinogenesis (Carcinogenesis, 12: 1051-1056, 1991; Cancer Res, 53: 3493-3498, 1993; Cancer Res, 53: 4182- 4188, 1993; Science, 257, 1349, 1992). These studies lead to consideration of Phase I and Phase II clinical trials funded by the NCI for colon and liver cancers. In addition, Dr. Rao’s laboratory provided evidence that PhIP- (food borne carcinogen) induced rat thymic lymphoma suppression by dietary oltipraz (Cancer Res, 56: 3395-3398, 1996). Although, many naturally- occurring organo-sulfur agents may provide the colon cancer chemopreventive effects; however, Dr. Rao’s research suggest that some of the isothiocyates, particularly synthetic aryl- isothiocyates such as PHITC had potent colon tumor promoter at higher concentrations (Cancer Res., 55:4311-4318, 1995).

 Genistein: a major soy Phytoestrogen attributed to cancer preventive effects of soy. Dr. Rao’s laboratory is first to carry out systemic studies using pure genistein on the possible colon cancer chemopreventive effects. Dr. Rao’s research provided evidence on the possible tumor promoting effects of genistein in colon cancer and importantly, his research showed that genistein may promote the colon tumorigenesis by suppressing 15-PGDH activity, a key enzyme

in the catabolism of PGE2 (Cancer Res., 57:3717-3722; 1997) At present number of laboratories focused on 15-PGDH as potential target for colon cancer prevention.

In addition to above, Dr. Rao’s research identified number of novel compounds from natural sources several of these agents various stages development

TYPE OF DIETARY FATTY ACIDS and FIBER: COLON CANCER PREVENTION

In mid 1980s it has been well-established that role of low-fiber and high amount of dietary fat as a major risk factors for colon cancer. However, it is not clear what types of fatty acid rich diets and their relative risk and importantly mechanisms by which these fatty acids influence the colon cancer risk. To understand the mechanisms by which different types of fatty acid rich diets on colon cancer risk; Dr. Rao utilized omega-3, omega-6 and omega-9 fatty acid rich diets in rat-AOM colon cancer model. Rao/CV 37

 Dr. Rao is first to show that omega-6 fatty acid rich diets enhance phosphorylation and

signaling of PKC and TPK, and activity of DAG, PLC-gamma1, PLA2, ODC and COX metabolism during the colon tumor progression and whereas omega-3 fatty acids oppose such activities (Lipids, 28: 441-447, 1993; Carcinogenesis, 14: 1327-1333, 1993; Cancer Res., 56:2314-2320, 1996; Cancer Res, 56: 532-537, 1996).  To further prove beneficial role of omega-3 fatty acids in humans, Dr. Rao in collaboration with German scientists provided first hand evidence on the effect of fish oil on the rectal cell

proliferation, PGE2 release and lack such effects in the presence of high fat diets in human clinical trials (Gastroenterology, 105:1317-1322, 1993; European J. Cancer Prev., 4:231-237, 1995).  Also, Dr. Rao’s research provided first evidence on diets rich mixed-lipids containing high saturated fatty acids diet (similar to American fat consumption) possesses 5-fold higher risk for colon cancer compared to low-fat (5%) omega-6 fatty acids diets or high fish oil (20% fat) diets (Cancer Res, 61:1927-1933, 2001).

Epidemiological and preclinical model studies provided convincing evidence that of all types of dietary fiber evaluated, wheat bran but neither corn bran or oat bran affords the most protection against colon tumor development. However, it is not clear what components of wheat bran provide protection. Dr. Rao and his collaborators in established role of wheat bran fractions in colon cancer.  Dr. Rao has identified the active component of wheat bran that reflects its inhibitory properties against colon cancer. He demonstrated for the first time that lipids and lipid-soluble components of wheat bran including phytosterols and tocopherols are most effective in inhibiting colon carcinogenesis suggesting that the lipid fraction of wheat bran contains bioactive agents that inhibit colon carcinogenesis (Cancer Res., 60: 4792-47-97, 2000).  Dr. Rao’s research also identified fiber derived from coffee, inulin, oligofrctose and pectin as potential prebiotics and Lactobacillus acidophilus NCFMTM and Bifidobactrium longum as probiotics in colon cancer prevention (Carcinogenesis, 181371-1374, 1997; Carcinogenesis, 19: 1815-1819, 1998 and Int. J. Oncology., 14:939-944, 1999). These pioneering studies by Dr. Rao and his associates lead to several clinical trials and number of guidelines from different agencies on the types fat and fiber consumption for human.

Genomic Instability and Colorectal Cancer: Dr. Rao’s other research contribution in understanding role mitotic spindle check point mutation in contribution to genomic instability, colon cancer development and drug resistance. Dr. Rao and his collaborators was first to establish the role of mitotic regulatory BubR1 role in colorectal cancer by establishing the transgenic haploinsufficient BubR1+/- mice (Cancer Res., 64: 440-445, 2004). Furthermore, Dr. Rao established compound mouse model of Apc-min.BubR1+/- to understand the genetic interactions of Apc and BubR1 in development of aneuploidy and colonic tumorigenesis (Proceed. Natl. Acda. Sci. USA, 102; 4365-4370, 2005; Carcinogenesis, 30: 1469-1474, 2009).

In summary, Dr. Rao’s research contributions are seminal and the sound scientific concept, principles and data his laboratory had developed over the years have significantly impacted the area of, nutrition and chemoprevention of colon cancer.

Dr. Rao has over 150 peer reviewed research publications in leading scientific and cancer research journals (>8,500 Citations; with average of 77 citations/citied article with h-index:43). Rao/CV 38

Dr. Rao is currently the principal investigator (six) or the co-principal investigator (one) on NIH/NCI grants (Three R01s, Two N01s, one RAPID, and one R21) with totaling >$14 million, focused on chemoprevention of areodigestive tract cancers. Also, he has been PI and Co-PI on previously awarded NIH/NCI peer-reviewed funding totaling over $42 millions. Dr. Rao is a member of the Board of Scientific Counselors/Reviewer of the National Cancer Institute. He was a member of Chemo/Dietary Prevention Study Section (CDP), Cancer Biomarkers Study Section (CBSS) and Metabolic Pathology Study Section (MP) at the National Institutes of Health. Dr. Rao served /active member of the NCI’s Cancer Drug Discovery, Biomarkers & Prevention, and Molecular Oncology (P01) program reviewer. He is part of Nutrient-Gene interaction and Cancer Chemoprevention Think Tank and the Review Panel for Chemopreventive Agent Development Research Group (CADRG), Division of Cancer Prevention at the National Cancer Institute. He has mentored a large number of graduate students and post doctoral fellows and has a large laboratory, including a number of research and research track Assistant Professors. Dr. Rao has been awarded young scientist award from the Council of Scientific and Industrial Research, India for developing technology to understand the role of methanogenic bacteria in natural environments. In 2007 Dr. Rao has been Awarded Outstanding Achievement in Cancer Research from AACR-Society of American Asian Scientists in Cancer Research. In 2008, the Board of Regents of the University of Oklahoma awarded the Regents Award for “Superior Research and Creative Activity

Load more

  38

Copy Link